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 Brucella is a genus of Gram negative, facultative intracellular pathogens which cause 
brucellosis, one of the most wide spread zoonotic diseases.  Brucellosis causes a severe 
economic burden due to reproductive loss in animals and human infection.  Vaccination of 
animals has proven to be the most effective means of controlling brucellosis; however the current 
live-attenuated vaccines are not considered ideal.  The live-attenuated vaccines Brucella abortus 
Strain 19 and RB51 remain pathogenic to humans, and the former interferes with diagnostic tests 
due to induction of antibodies against the O-polysaccharide.  DNA vaccination with single 
antigens has proven to be successful at protecting mice against B. abortus challenge, however 
this method is less effective in large animals.  Immunization with a combination of antigens has 
been shown to provide more protection than single antigens.   
In an attempt to develop a better DNA vaccine, two multivalent multi-epitope plasmids 
were constructed using known protective antigens and bioinformatics technologies.  Epitopes 
predicted to induce cell-mediated immunity were selected from Cu/Zn superoxide dismutase, 
outer membrane protein (Omp) 16, Omp19, ribosomal subunit L7/L12, BP26, ribosomal subunit 
L9, and Omp25.  The plasmids were transfected into Chinese hamster ovary (CHO K1) cells, and 
PCR was used to confirm presence of the sequences in the genome.  The transcription of the 
BabV1 and BabV2 genes to RNA was confirmed using RT-PCR.  Finally, Western blots using 
sera from Strain 19 infected goats suggest the protein is not recognized by the humoral response 
of vaccinated animals.  Further research is required to determine if the p425/BabV1 and 










Brucella is a genus of Gram negative, facultative intracellular pathogens which cause 
brucellosis, one of the most widespread global zoonotic diseases [1, 2].  Infection in cattle causes 
abortion and infertility; and in humans, undulant fever, arthritis, endocarditis and spondylitis [3, 
4].  The Brucella spp. are named based on their natural host with B. melitensis for goats, B. 
abortus for cattle, B. suis for swine, B. canis for dogs, B. ovis for sheep, and B. neotomae for 
desert mice [5].  Smooth Brucella species express full lipopolysaccharide (LPS) molecules, 
while rough Brucella spp. lack O-polysaccharide antigen (OPS) of the LPS [6, 7].  The brucella 
OPS is a homopolymer of 100 residues of 4-formamido-4, 6-dideoxymannose linked by 
predominately α-1,2 bonds in A epitope strains or α-1,3 bonds every fifth residue in M epitopes 
strains [8].  Brucella spp. are aerobic, fastidious, slow growing, and require supplemental CO2, 
thiamine, nicotinamide, biotin, and serum for growth [9, 10].   
Humans may be exposed by ingestion of unpasteurized milk from infected animals; 
contact with infected tissue, blood, lymph; or inhalation of aerosols [2, 6, 11].  Globally, there 
are approximately 500,000 cases of human brucellosis reported each year resulting in high 
economic burdens due to animal brucellosis in developing countries [12, 13].  One of the most 
effective means of controlling brucellosis, in both humans and animals, is vaccination of animals 
[14, 15].  The live-attenuated vaccines B. abortus Strain 19 and rough B. abortus Strain 51 
(RB51) grant protection against abortion and infection caused by B. abortus in cattle, and the 
live-attenuated vaccine Rev. 1 protects against B. melitensis in goats and sheep [5, 14].  Though 
they are effective in protecting against brucellosis, these are not considered ideal vaccines due to 
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residual virulence in humans; ability to cause abortion in pregnant animals; and in smooth 
strains, such as Strain 19 and Rev. 1, induction of anti-OPS antibodies that interfere with 
serological tests [14, 16].  There is currently no vaccine available for use in humans or wildlife 
reservoirs [17].   
The goal of this research project was to determine if it is possible to design a DNA 
vaccine recognized by the humoral immune response of vaccinated animals.  A combination of 
literature mining and bioinformatics technologies was used to select protective epitopes against 
B. abortus infection.  Plasmids coding for these epitopes were constructed and transfected into 
Chinese hamster ovary (CHO K1) cells.  The CHO K1 genome was then analyzed via PCR to 
determine the presence of the vaccine sequences.  Transcription of the vaccine sequence into 
RNA was determined via RT-PCR.  Finally, media and cell lysate from the CHO K1 cells were 
analyzed via Western blot using Strain 19 vaccinated goat sera to detect the recombinant 
proteins. 
ADAPTIVE IMMUNE RESPONSE 
 The immune system is divided into the innate and adaptive systems [18].  The innate 
immune system is the first line of defense against infection and has no immunological memory 
[18].  On primary exposure, the adaptive immune system develops a specific memory response 
that is recalled on subsequent exposures [18].  The adaptive immune system is divided into cell-
mediated, which consists of CD4+ and CD8+ T cells, and humoral immunity, which consists of 
B cells and antibodies.  Vaccines induce an adaptive immune response which is recalled on 
secondary exposure.  During the development of an adaptive cell-mediated response, naïve 
CD4+ and CD8+ T cells differentiate and proliferate when stimulated by cytokines, 
costimulatory molecules, and antigen presenting cells (APC) displaying an epitope in the context 
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of Major Histocompatibility Complex (MHC) molecules recognized by the T cell receptor [19, 
20].  The cytokines and costimulatory molecules that the naïve T cells are exposed to during 
differentiation determine the effector function of the differentiated cell [19, 21].  A number of 
these differentiated T cells become memory cells which are recalled rapidly on secondary 
exposure [22].   
 Interleukin-12 (IL-12) causes naïve CD4+ cells to differentiate into Type 1 T helper 
(Th1) cells which secrete IL-18, IL-2, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) 
[19, 23].  The latter three cytokines are capable of activating macrophages and CD8+ cells to kill 
intracellular pathogens, such as Brucella spp. [19].  Type 2 T helper (Th2) cells are differentiated 
by IL-4 stimulation and secrete IL-4, IL-5 and IL-10 [19].  Th2 cells promote antibody, primarily 
IgG1 and IgE, production by B cells and are therefore considered to be a regulator of the 
humoral immune response [19].  In addition, IL-2 promotes T cell proliferation and survival; and 
is important for both Th1 and Th2 differentiation [23-25].  Th17 cells are produced when naïve 
CD4+ T cells are stimulated by both IL-6 and transforming growth factor-β (TGF-β) and secrete 
IL-17 [19].  IL-17 is able to activate various cell types to produce pro-inflammatory cytokines 
and molecules such as IL-6, IL-1β, TNF-α, and nitric oxide (NO) [26].  
CD8+ cells kill infected host cells through secretion of granzyme and perforin as well as 
secretion of cytokines such as TNF-α and IFN-γ [21, 27].  Although the exact mechanisms are 
unclear, establishment of memory CD8+ cells and their effector function upon secondary 
exposure depends on CD4+ T cell help, antigen avidity, and cytokine stimulation [21, 24, 25].  
Indeed, CD8+ cells that differentiate in the absence of CD4+ cells during primary infection show 
reduced proliferation and cytokine secretion [21, 25].   
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 Major Histocompatibility Complex are a class of molecules which bind to and present 
processed peptide epitopes on the surface of cells for T cell recognition [28, 29].  Epitopes, also 
known as antigenic determinants, are the minimum essential portions of antigens recognized by 
the immune system [27, 30].  Linear epitopes are epitopes with amino acid residues adjacent in 
sequence [31], while conformational epitopes are formed by residues that are discontinuous but 
close in three dimensional space [32].  MHC I molecules are displayed on the surface of all 
nucleated cells and present endogenous linear epitopes that are 8-11 amino acids (mostly 
nonamers) long to CD8+ T cells [27, 29, 33].  MHC II molecules are displayed on the surface of 
APCs and present exogenous 13-30 amino acid long epitopes to both CD4+ T cells (linear 
epitopes) and B cells (linear and conformational epitopes) [27, 33, 34].   
TH1 RESPONSE 
Resistance to brucellosis is primarily mediated by a Th1 immune response, mainly due to 
IFN-γ activation of macrophages [5, 17, 35-38].  CD4+ and CD8+ T cell subsets have also been 
shown to be involved in resistance against infection by production of cytokines, such as IFN-γ 
and TNF-α, and cytotoxic killing of infected macrophages [5, 17, 27, 35, 37-43].  Studies on the 
depletion and passive transfer of T cell subsets have revealed that both CD4+ and CD8+ cells 
contribute to resistance, and protection is greater when both subsets are present [39, 40].  
Exogenous IL-2 in culture with B. abortus Strain 19, Strain RB51, and virulent Strain 2308 
infected macrophages reduced the replication of bacteria at 24 hours but not at 48 hours [42].  
However, addition of IL-2 to IFN-γ activated macrophages neither enhanced nor inhibited 
control of infection [42].   
Both CD4+ and CD8+ produce IFN-γ in response to brucella infection [37].  IFN-γ is 
crucial for the control and clearence of brucellosis in the animal model [37, 38, 44].  IFN-γ 
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enhances resistence by increasing the production of reactive oxygen species (ROS) by 
macrophages, and the amount of IFN-γ produced by both murine CD4+ cells and splenocytes 
correlates with resistance to brucellosis [38].  Exogenous IFN-γ in macrophage culture increased 
anti-brucella activity, including increased ROS production. and reduced replication in the 
infected IFN-γ activated macrophages [38, 42, 44].  IFN-γ neutralization by anti-IFN-γ 
monoclonal antibodies (mAb) and IFN-γ gene knock out mice show increased splenic colony 
forming units (CFU) in both naturally susceptible BALB/c and naturally resistant C57BL/6 mice 
one week post infection [38, 43, 44].  Both resistant and susceptible IFN-γ knock out mice die by 
six and 12 weeks post infection, respectively [38].  Resistant mice produce IFN-γ at all measured 
time points during infection, while susceptible mice stop producing IFN-γ between weeks three 
and six [38].  During this IFN-γ hiatus CD8+ cells and TNF-α control the infection, but are 
unable to clear brucellae from the animal [38].   
Tumor necrosis factor-α enhances resistance to brucella infection during the first two to 
three weeks of infection in both wild type (WT) and IFN-γ knock out mice [43, 45] however, 
splenic CFU in TNF-α deficient mice were similar to control mice by six weeks post infection 
[45].  In both the presence and absence of IFN-γ, TNF-α has been shown to enhance macrophage 
killing of Brucella spp., but it is not able to clear brucella infection in vivo [38, 43, 46].  Further, 
mice deficient in TNF receptors (TNFR-/-) were less able to control brucellosis and produced 
neglible quantities of IL-12 from splenic cells of Strain 19 infected C57BL/10 mice in the first 
two weeks of infection [47], suggesting that TNF-α indirectly promotes the development of a 
Th1 response [45].  These data suggests that TNF-α plays both a direct and indirect role in 





The contribution of IL-4 to brucellosis susceptibility is controversial [48, 49].  The 
addition of exogenous IL-4 to IFN-γ activated macrophages did not inhibit or enhance control of 
brucella infection in vitro [42].  IL-4 deficient C57BL/6 mice, but not BALB/c mice, are more 
resistant than WT to B. melitensis when analyzed on days 5, 12 and 28 post infection [48].  
However, IL-4 deficient BALB/c do not show enhanced resistance at these time points [48].   IL-
4 neutralization with mAb reduces the splenic CFU of less virulent B. abortus Strain 2308 from 
both BALB/c and C57BL/10 mice but only at lower challenge doses [49].  IL-4 is also an 
important survival factor for B cells thus generating an antibody response [50].  IL-4 
neutralization reduced antibody production and indirectly promoted a Th1 response [49].  This 
suggests that the deleterious effects of IL-4 are mediated by inhibition of Th1 development and 
not directly on macrophage killing of Brucella organisms.   
Interleukin-10 has been shown to increase susceptibility to brucellosis in the mouse 
model [17, 38, 44, 49].  BALB/c mouse splenocytes and B cells produce significant amounts of 
IL-10 after infection with B. abortus [37, 38].  Addition of IL-10 to brucella-infected 
macrophage cultures reduced control of infection both in the presence and absence of exogenous 
IFN-γ [44].  Interleukin-10 is also known to suppress IL-12 production, indirectly suppressing 
the Th1 response and IFN-γ production [44, 51, 52].  Taken together, this indicates IL-10 both 
directly and indirectly increases susceptibility to brucellosis. 
TH17 RESPONSE 
The Th17 response is an important mediator of mucosal immunity against both 
extracellular and intracellular pathogens [53].  However, its role in mucosal and systemic 
immunity to brucellosis has not yet been clearly defined despite exposure commonly occuring 
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through mucosal routes [48, 54, 55].  The Th17 response does not appear to have an important 
role in the primary infection of BALB/c or C57BL/6 mice against Brucella spp.; however it has 
been shown to be protective in the adaptive response of BALB/c mice vaccinated with RB51 [48, 
54, 56].  This is consistent with a study that found vaccinating cattle with Strain 19 or RB51 
induces Th17 cells and IL-17 production which peaked one year after vaccination [57].  The 
amount of protection an adaptive Th17 response against brucellosis grants varies based on 
vaccine, as neutralization of IL-17 with mAb ranges from complete abbrogation to only a slight 
reduction in protection [48, 54, 56].  While evidence suggests that a Th17 response is not 
necessary for clearance or protection against brucella infection, it is capable of working 
synergystically with the Th1 response to enhance protection; and IL-17 compensates to a degree 
for a lack of IFN-γ [48, 56].   
B CELLS  
The effector functions of B cells include antibody production and cytokine secretion [58].  
Both BALB/c and C57BL/6 B cell deficient mice clear Brucella bacteria more rapidly than WT 
mice through an antibody independent mechanism [37].  Indeed, B cell deficient BALB/c and 
C57BL/6 mice produced significantly less TGF-β and IL-10, respectively three weeks post 
infection, suggesting that B cells enhance susceptibility to brucella infection through both IL-10 
and TGF-β dependent mechanisms [37].  The antibody response to Brucella spp. is protective but 
not necessary for immunity [5, 40, 59, 60].  Passive transfer of anti-OPS and anti-outer 
membrane protein (Omp) antibodies provide protection to mice against brucellosis [17, 61-67].  
However, the rough vaccine strain RB51 does not cause the production of anti-OPS antibodies 
[5, 60].  Furthermore, the antibody-mediated protection against membrane proteins is reduced in 
smooth strains due to steric hinderance from the OPS of Brucella spp. [63].  Taken together, B 
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cells are capable of both a detrimental or beneficial role in the adaptive immune response against 
brucellosis. 
BRUCELLA ABORTUS VACCINES 
It is important to study and refer to the immune responses induced by vaccines known to 
provide protective immunity in order to develop more effective vaccines [57].  The mouse model 
is the standard model for brucellosis vaccine and immunity research [17].  The information from 
this model is not always transferable, but is useful because of the cost and time limitations of 
using the target species cattle as a model for B. abortus vaccine research [17, 68].  The B. 
abortus live-attenuated vaccines Strain 19 and RB51 are the most widely used vaccines in cattle, 
[69] making them good reference vaccines.  The current characteristics of an ideal brucellosis 
vaccine are: [11, 70].   
 Live strain capable of inducing a strong Th1 response 
 Does not induce anti-OPS antibodies that interfere with serological tests 
 Attenuated and incapable of causing disease or persistence in humans or animals  
 A single dose induces long-lasting protection against abortion and systemic or 
uterine infection 
 Does not revert to virulence 
 Does not cause seroconversion on revaccination 
 Inexpensive and easy to produce and administer  
 The first vaccine widely used for the control of bovine brucellosis was the live-attenuated 
B. abortus Strain 19 [14], which was originally isolated from the milk of a jersey cow by Dr. 
John Buck in 1923 [69].  Even though it is effective at controlling brucellosis and inducing 
protection that lasts the entire productive lifespan of an animal, there are undesirable 
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characteristics [69].  Some animals remain chronically infected and secrete Strain 19 in milk 
[69].  As a smooth strain, Strain 19 induces anti-OPS antibodies which make it difficult to 
distinguish from vaccinated and naturally infected animals [69].  Strain 19 also maintains a low 
level of virulence, may cause abortion in pregnant cattle, and remains pathogenic to humans 
[69].   
 The characteristics of the immune response induced by Strain 19 are a Th1 biased, IFN-γ 
production, antibody production, CD4+ cells, and cytotoxic CD8+ cells in both mice and cattle 
[57, 69].  Cattle display memory CD4+, CD8+, and B cells on day 210 post vaccination [57, 71].  
In cattle, it was determined that CD4+ cells are the primary source of IFN-γ, while CD8+ cells 
didn’t produce significant IFN-γ [57, 72].  Further, no IL-4 was detected and CD4+ cells were 
also determined to be the main source of IL-17 [72].   
The interference with serological tests and potential for abortion in cattle are the main 
reasons Strain 19 was replaced with RB51 [69, 73].  RB51 is a stable rough mutant derived from 
B. abortus virulent Strain 2308 passaged on media containing low concentrations of rifampicin 
and selecting for rough morphology [69, 74].  As an attenuated rough strain, it does not induce 
anti-OPS antibodies and shows reduced colonization in animals [69, 74, 75].  In addition to 
cattle, RB51 has been shown to protect water buffalo against B. abortus and protects mice 
against B. abortus, B. melitensis and B. ovis [59, 75].  However, RB51 is also pathogenic to 
humans, resistant to rifampicin, and not safe for use in pregnant cattle [69].   
In both mice and cattle, RB51 induces a strong Th1 response.  This includes IFN-γ 
production, CD4+ cells, cytotoxic CD8+ cells, and no detectable IL-4 [57, 69].  Similarly to 
Strain 19, CD4+ cells are the main source of IFN-γ and IL-17 [49, 57, 76].  It should also be 
noted that IL-17 neutralization in RB51 vaccinated mice significantly reduced protection against 
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B. melitensis, suggesting an important role for the Th17 response in RB51 induced protection 
[77].  Further, passive transfer experiments revealed that CD8+ cytotoxic activity was positively 
correlated with IFN-γ levels, suggesting that both T cell subsets are important for optimal 
protection [76].   
A key difference between the memory cells generated in cattle by RB51 and Strain 19 is 
that memory CD4+ and CD8+ cells are induced by both vaccines, but RB51 does not induce 
memory B cells indicating the humoral response is not important for protection in cattle [57].  
CD8+ cells from RB51 vaccinated cattle are granzyme B+ and perforin+, while Strain 19 CD8+ 
cells are only granzyme B+ [57].  CD8+ cells that secrete granzyme have cytotoxic activity, and 
cytotoxicity via the perforin pathway has been shown to provide protection against B. melitensis 
in mice [78, 79].   
Passive transfer experiments in mice found that T cells from both RB51 and Strain 19 
vaccinated mice protected naïve mice from challenge against B. abortus, although Strain 19 
protection was significantly greater than that conferred by RB51 [59].  Further, serum from 
RB51 vaccinated mice provided no protection against B. abortus while the Strain 19 vaccinated 
mice serum did [59].  The main difference between the immune responses following Strain 19 
and RB51 vaccination of cattle can be generalized by stating that Strain 19 is CD4+ directed 
while RB51 is CD8+ directed [57].  Further, Th17 and humoral responses appear to enhance 
RB51 and Strain 19 induced protection, respectively [40, 77].  
CONCLUDING REMARKS: IMMUNOLOGY 
A vaccine against brucellosis must induce a strong Th1 immune response, including both 
CD4+ and CD8+ cells, to effectively control infection [5, 17, 35-38].  However, the roles of 
antibodies, Th2, and Th17 differ between the two commercial B. abortus vaccines, indicating 
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that protection against Brucella spp. is best optimized when multiple arms of the immune system 
are stimulated [17, 40, 49, 57, 61-63].  Indeed, antibody opsonized Brucella bacteria are more 
readily phagocytosized and killed more efficiently in IFN-γ activated macrophages; however a 
small number of bacteria survive and replicate in the macrophage [80].  CD8+ cells lyse infected 
macrophages and release the intracellular bacteria to be exposed to another round of 
opsinization, phagocytosis, and IFN-γ enhanced killing [3, 79, 81, 82].  It is important to balance 
these responses when designing a new vaccine.  Differentiation of naïve T cells into Th17 
requires stimulation by TGF-β, which also downregulates both the Th1 and Th2 differentiation 
signalling pathways [26].  However, an adaptive Th17 response has been shown to enhance the 
Th1 mediated protection to brucella infection [77].  Th2 cytokines inhibit IL-12 production and 
promote antibody production [50, 83].  To achieve maximum protection, a brucellosis vaccine 
must sufficiently stimulate a Th2 and Th17 response from the immune system without inhibiting 
the development of a Th1 response.   
OTHER VACCINATION METHODS  
 There are currently no ideal vaccine candidates against brucellosis.  As stated previously, 
the current live-attenuated strains possess safety concerns [69].  Heat-killed Brucella bacteria 
and protein subunit vaccines induce lower protection and a Th2 biased response [84, 85].  The 
challenge of developing safe brucellosis vaccines capable of stimulating multiple arms of the 
immune system may be addressed by using multiple design strategies.  DNA vaccination has 
been shown to efficiently stimulate both Th1 and Th2 responses, and including multiple epitopes 
or epitope dense regions from several antigens induces a broad immune response [15, 85-93].  A 
DNA vaccine using six nonamer epitopes from different B. abortus antigens induced a protective 
response in the murine model [94].  The overall efficacy may be improved by targeting the 
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immune response to conserved and relevant antigens [89, 95-98].  Therefore, a multi-epitope 
DNA vaccine against B. abortus may provide increased safety, cross protection, and efficacy 
compared to the current live-attenuated vaccines. 
DNA VACCINATION 
 DNA vaccination is an immunization method where a DNA plasmid encoding the desired 
antigen is injected into the host, enters host cells, is then expressed endogenously; and the 
antigen is secreted from the cell [85, 86].  DNA vaccines are safer than live-attenuated vaccines 
which have the possibility of reverting to virulence [15, 85].  They are also simpler to 
manufacture, have lower production costs, are less temperature sensitive, and possess a longer 
shelf life than most conventional vaccines [15, 85].  A crucial advantage of DNA vaccination is 
the ability to stimulate a strong cell-mediated response, Th1 [15, 85, 86].  Additionally, the CpG 
oligodeoxynucleotide (CpG) motifs of bacterial DNA serve as an adjuvant that activates 
macrophages and dendritic cells, through Toll-like receptor 9 (TLR-9), to secrete IL-12, IFN-γ 
and TNF-α [86, 99].  The expressed antigens are processed and presented via both MHC I and 
MHC II, which allows both a Th1 and Th2 response to be stimulated [85, 87, 88].  Due to both 
the safety and the ability to stimulate Th1 immunity, DNA vaccines are seen as a potential 
alternative to the current live-attenuated vaccines against Brucella spp. [15].  DNA vaccination 
against brucellosis has been well researched and has shown success in the mouse model [15, 87, 
88, 94, 100-108]; however, there is no DNA vaccine against brucellosis in large animals.  
 DNA vaccines are promising but still have disadvantages.  This type of immunization is 
limited to protein antigens, may induce tolerance, and the bacteria or parasite antigens are 
susceptible to unusual processing [109, 110].  While DNA vaccination in mice has been shown 
to be effective, low immunogenicity has been a consistent issue in larger animals, including 
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primates and humans [111].  Further, mice often require multiple high doses that cannot be 
proportionally applied to large animals [112, 113].  Successful DNA vaccination is also limited 
by the transfection rate of target cells and expression rate of the antigen once the DNA enters the 
cell [112, 113].  Unprotected DNA is rapidly degraded in the extracellular space, and DNA must 
be up taken by the nucleus of host cells to be expressed [112, 113].  Methods to overcome these 
limitations exist and are being researched to further improve efficacy of DNA vaccination.  
Electroporation and DNA encoding co-stimulatory molecules targeting APCs has been shown to 
increase immunogenicity [114].  Further, classical and genetic adjuvants are being researched to 
enhance immunogenicity [115].   
MULTI-EPITOPE VACCINES 
Antigen presenting cells present MHC I and MHC II epitopes to CD8+ and CD4+ cells 
respectively [19].  While single epitope vaccinations have been shown to induce protective 
immune responses, including multiple epitopes and antigens may result in a more complete 
response and increased protection [27, 67, 89, 116-122].  Multi-epitope vaccines are also able to 
provide wide population coverage, protect against pathogens with complex life cycles, and 
induce cross protection [89, 98, 123-125].  It is possible to simultaneously prime responses to 
multiple specific MHC I epitopes with a single MHC II helper epitope [89].  It has been shown 
that a single short or long peptide containing intrinsic epitopes with broad MHC binding 
potential or MHC I and II epitopes specific for multiple MHC alleles is capable of producing a 
strong immune response in all relevant haplotypes of a population [89, 90].  Immunization with 
single epitopes, multiple epitopes, and immunodominant regions of antigens has been shown to 





The development of both the specific cytotoxic and antibody response is heavily 
influenced by CD4+ cell interactions with CD8+ cells and B cells, respectively, indicating that 
protection induced by epitope based vaccines is maximized when MHC I, MHC II, and B cell 
epitopes are all present [121, 126-129].  Indeed, immunization with MHC II epitopes, also 
known as CD4+ ‘helper’ T cell epitopes, has been shown to induce protection against pathogens 
and enhance the immune response towards MHC I and B cell epitopes and are therefore 
considered to be crucial in the development of epitope based vaccines [89, 116, 117, 121, 126-
130].  Furthermore, it is not necessary for these epitopes to originate from the same antigen or 
pathogen for CD4+ dependent enhancement to occur, which allows for the creation of 
multivalent vaccines [116, 117, 127, 129, 131, 132].  A disadvantage of this reliance of MHC II 
epitopes is that failure to elicit a sufficient CD4+ T cell response may result in lower 
immunogenicity of the vaccine as a whole [133].  The use of promiscuous MHC II epitopes, 
regions dense with multiple MHC II epitopes, or long peptide sequences containing multiple 
epitopes has been successful at overcoming this issue [90, 92, 121, 128, 129, 134, 135].  
Furthermore, optimal CD4+ enhancement of B or CD8+ cell response is achieved when the 
epitopes are collinearly linked [89, 116, 127-129].    
CROSS PROTECTION  
On farms where small ruminants and cattle intermingle, B. melitensis may be transmitted 
between the two species; therefore, a vaccine capable of inducing cross protection against 
multiple Brucella spp. is desired [136, 137].  Multi-epitope vaccines induce cross protection by 
the delivery of several antigens at once or concentrating the immune response on a small number 
of conserved epitopes rather than polymorphic epitopes [67, 97, 123, 138-141].  DNA/DNA 
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hybridization studies revealed that members of the genus Brucella share over 90%  homology 
[142], and other studies have shown that immunization with immunodominant conserved regions 
of antigens is effective at inducing cross protection [67]. 
ANTIGENS 
Antigen Protection IFN-γ TNF-α 
Cytotoxic 
CD8+ Other Information Source 
Cu/Zn 




BP 26 1.6 - 2.6  + NA NA 




Omp19 1.38 - 1.85 + NA NA 
Mucosal protection, 
activates DC, induces IL-17, 
protective antibodies 
[39, 53, 54, 
67] 
Omp16 1.15 -1.97 + NA NA 
Activates DC, mucosal 




Omp25 1.39 - 2.7 + + + Antibodies are protective 
[64, 101, 
150, 151] 
L9 1.96 - 2.55  + + NA Protection is CD8+ mediated [15, 152] 




Table 1.1: Antigen Characteristics 
Table of antigens included in the DNA vaccines.  Systemic protection induced by the antigen 
against B. abortus or B. melitensis was determined by log CFU reduction recovered from spleen 
of challenged mice determined at 7-30 days post infection.  Characteristics of the immune 
response induced by vaccination with the antigen of interest, including IFN-γ and TNF-α 
production and induction of specific CD8+ cytotoxic activity.  Sources indicate whether the 
antigen produces (+), does not produce (-), or if no data was found (NA) with regards to the 
characteristic of the immune response.   
CU/ZN SUPEROXIDE DISMUTASE 
The Brucella spp. express an immunogenic 18.5-20 kDa periplasmic Cu/Zn superoxide 
dismutase (SOD) [87, 108, 147], a class of enzymes which allow bacteria to survive the 
respiratory burst of phagocytes [156, 157].  B. abortus SOD deletion mutants display reduced 
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survival during early infection in vivo [158].  Strain 19 and RB51 vaccinated cattle and mice do 
not produce a humoral or cell-mediated immune response against SOD [122, 143], indicating 
that SOD is not a necessary antigen for a protective immune response [122].  However, 
immunization with SOD has been found to consistently grant protection against brucellosis when 
administered in the form of either recombinant peptides, DNA vaccines, whole recombinant 
proteins, overexpression mutants, or through co-immunization with other antigens [87, 88, 100, 
103, 107, 108, 146, 147].   
Mutant strains of RB51 overexpressing SOD (RB51SOD) provided greater protection 
than the parental strain in mice, without increased survival or persistence [143, 145, 146].  Only 
the RB51SOD vaccinated group produced IFN-γ when splenocytes were stimulated with rSOD 
[143].  IgG2a was the only detected antibody isotype against Cu/Zn SOD in RB51SOD 
vaccinated mice [143].  Taken together, this indicates that SOD produces a Th1 response when 
overexpressed in RB51 vaccinated mice [143].  Another RB51-SOD overexpression mutant 
provided significantly greater protection against B. suis in mice than parental RB51 at two weeks 
post challenge, indicating SOD is a cross protective antigen [145].  
 In mice, DNA vaccinations encoding SOD have consistently induced protection at two to 
four weeks following challenge and display a Th1 biased immune response characterized by 
IFN-γ producing CD4+ cells, specific CD8+ cytotoxic activity, splenocyte proliferation, and low 
or no detectable IL-10 and IL-4 [87, 88, 103, 108].  Depending on route of immunization and 
dosage, both CD4+ and CD8+ have been observed to be the primary source of IFN-γ [87, 103].  
Nasal vaccination with SOD-DNA produces both IgG2a and IgA antibodies as well as CD8+ 
splenocytes and systemic protection against B. abortus in mice [108].  SOD DNA vaccinated 
calves showed significant IgG1 and IgG2a titers and IFN-γ+ peripheral blood monocytes 
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(PBMC) but no detectable TNF-α or IL-4 on stimulation with rSOD or crude brucella proteins 
[144].  
 Mice vaccinated with the synthetic SOD peptide GGAPGEKDGKIVPAG, with or 
without adjuvant, showed significant protection two weeks following B. abortus challenge [147].  
The GGAPGEKDGKIVPAG peptide vaccinated mice produced significant amounts SOD 
specific IgG antibodies [147].  Pratt et al. hypothesized that antibody binding to the 
corresponding epitope in the whole protein may inhibit SOD function therefore the bacteria will 
be more susceptible to the respiratory burst [157].  To our knowledge this has not been tested.  
This peptide is not recognized by the humoral or cell-mediated immune response of cattle 
vaccinated with Strain 19 or RB51 [122].    
BP26 
BP26, also known as Omp28 [152], is a 26 kDa periplasmic protein of unknown function 
that is immunogenic and immunodominant in cattle, dogs, goats, sheep, and humans [60, 159].  
BP26 is highly conserved between B. melitensis, B. abortus, B. ovis, B suis and B. neotomae 
[148, 149, 160].  A Strain 19 mutant with the BP26 gene deleted (S19ΔBP26) maintained the 
same residual virulence and protection as parental Strain 19 in BALB/c mice and cattle [60, 
159], indicating that BP26 is not necessary for protective immunity to brucellosis [60].  
However, BP26 is capable of inducing both humoral and cell-mediated responses and is 
protective as a subunit or DNA vaccine [56, 149, 160, 161].   
Immunization with recombinant BP26 in BALB/c mice resulted in approximately 2.6 
logs of protection against B. abortus 10 days post-infection [148].  DNA vaccination with BP26 
resulted in 1.16 log less CFU in the spleen of BALB/c mice when challenged with B. melitensis 
[149].  Twelve epitopes of BP26 are capable of inducing IFN-γ secretion from PBMCs of sheep 
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between 1 to 7.5 months after vaccination with B. melitensis M5-90 [160].  BP26 DNA 
vaccination is capable of producing IFN-γ and both specific CD4+ and CD8+ cells in sheep and 
bison [56, 160], suggesting this antigen is a candidate for immunization in multiple animal and 
Brucella species.   
OMP19 
 Omp19 is an 18-19 kDa outer membrane surface exposed lipoprotein that is associated 
with virulence and present in all biovars of the six classical Brucella species [39, 54, 60, 159].  
Strain 19 and virulent B. abortus Omp19 deletion mutants are attenuated in mice, do not confer 
protection against B. abortus challenge in heifers, and display reduced growth in solid media [60, 
159, 162].  Further, CD4+, CD8+ and antibodies specific to Omp19 are capable of inducing 
systemic and mucosal protection against brucellosis [39, 67]. 
Mice immunized with rOmp19 or an immunodominant region of Omp19 (amino acids 21 
– 177) display systemic protection against both B. melitensis and B. abortus when challenged 
[39, 53, 67].  Monoclonal antibodies against Omp19 protect mice from challenge with the rough 
strain B. ovis [39] and bind to heat-killed rough strain RB51 but not smooth strain B. abortus 
544.  This suggests steric hindrance due to OPS interference with antibodies binding to the 
surface exposed Omp19 motifs [39].  However, sera from mice immunized with rOmp1921-177 
protected macrophages from cytopathic effects of both B. abortus and B. melitensis in vitro [67], 
suggesting that concentrating the antibody response on this region is an effective immunization 
strategy.   
Splenocytes from both whole rOmp19 and rOmp1921-177 vaccinated mice produce IFN-γ 
and IL-12 but not Th2 cytokines on stimulation [39, 53, 67].  The IFN-γ producing cells were 
determined to be CD4+ and CD8+ cells; and depletion of either subset reduced, but did not 
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completely eliminate, protection against challenge [39].  Recombinant Omp19 has also been 
shown to activate dendritic cells and provide mucosal protection against B. abortus [39, 54].  
Intragastric (i.g.) immunization of mice with rOmp19 has been shown to induce a Th1 and Th17 
response while intraperitoneal (i.p.) vaccination only induced a Th1 response [39, 53, 54].  This 
oral protection is Th17 dependent [54].   
OMP16 
 Omp16 is a 16.5 kDa outer membrane surface exposed lipoprotein expressed in all 
biovars of the classical Brucella species [39, 104].  No successful Omp16 deletion mutant has 
been produced in any of the Brucella spp. [163], suggesting that this protein is necessary for 
survival.  Omp16 acts as an adjuvant by activating the CD8α+ subset of dendritic cells both in 
vivo and in vitro in C57BL/6 mice [41].  This activation is dependent on TLR-4 in vivo but not in 
vitro [41]. 
 Vaccination with both Omp16-DNA and rOmp16 induces specific IFN-γ+ splenocytes, 
antibodies, and no detectable Th2 cytokines [39, 41, 104].  Monoclonal antibodies against 
Omp16 have been shown to provide significant protection in mice against B. ovis challenge [39, 
104].  In rOmp16 vaccination, antigen specific CD4+ and CD8+ cells were found to contribute to 
the production of IFN-γ; and depletion experiments revealed that both subsets provide significant 
protection, but the protection is greatest when both populations are present [39].  Omp16 with 
cholera toxin and i.g. immunization of mice provided significant protection at four weeks post 
oral challenge with B. abortus similar to RB51 [39, 41].  In summary, vaccination with Omp16 
induces a strong Th1, humoral response, and mucosal protection against multiple Brucella spp. 





 Omp25 is an immunogenic, surface exposed, 25 kDa transmembrane protein that is 
highly conserved [64, 150, 164].  Immunization with Omp25 inconsistently results in TNF-α 
production which is contradictory to evidence that Omp25 of B. suis inhibits TNF-α production 
in human macrophages and allows secretion of periplasmic proteins in acidic medium [64, 101, 
150, 151, 165].  Deletion of Omp25 in Brucella spp. results in lower persistence within the 
animal and reveals Omp25 is not necessary for protection against smooth and rough Brucella 
spp. in mice or goats [164, 166, 167].  Omp25 is also known to bind the outer membrane to the 
peptidoglycan layer [150, 164], which suggests a role in membrane stability, persistence, TNF-α 
inhibition, and adaptation to acidic environment.  While deletion mutants indicate that Omp25 is 
not necessary for protection against Brucella spp., it is still a known protective antigen against B. 
abortus and B. melitensis [101, 151].   
In sheep, as many as 91% of B. melitensis infected sera contain antibodies to Omp25 
[101], indicating that Omp25 is both immunodominant and broadly recognized.  Further, 
antibodies against Omp25 provide limited but significant protection against B. melitensis [64], 
which suggests that a vaccine incorporating Omp25 may induce protective antibodies in a large 
percentage of the population. 
 Mice vaccinated with plasmid DNA encoding Omp25 displayed significant protection 
against B. melitensis 15 days post challenge, and no bacteria were recovered from three of five 
mice [101].  Splenocytes from mice vaccinated with Omp25 coding plasmid DNA displayed 
significant production of IFN-γ and TNF-α, but not IL-4 or IL-10, on stimulation with rOmp25 at 
weeks 5, 8, 11 and 21 following initial vaccination [101], indicating that a memory Th1 immune 
response was induced.  Splenocytes from mice vaccinated with rOmp25 produced significant IL-
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12, IFN-γ, TNF-α, IL-4, and IL-6 on stimulation with rOmp25 [150].  Recombinant Omp25 also 
induces in both CD4+ and CD8+ cells cytotoxic killing of infected macrophages [151].  In 
conclusion, Omp25 displays several desirable features for a brucellosis vaccine such as the 
induction of protective antibodies and a strong Th1 response, including IFN-γ, TNF-α and 
specific cytotoxic CD8+ cells [64, 101, 150, 151].  
RIBOSOMAL L9 
 L9 is a conserved 50S ribosomal protein in Brucella spp. [152].  Vaccination with 
recombinant or DNA L9 produces IgG isotype one week post vaccination [15, 152].  When 
stimulated with rL9, splenocytes from L9 DNA vaccinated mice produced significant quantities 
of both IFN-γ and TNF-α.  However, IL-2 production was only significant when the DNA 
vaccine was introduced through electroporation; and IL-4 was only detected in rL9 + Alum 
vaccinated mice [15, 152].  Overall, the IFN-γ producing CD8+ cell population was significantly 
larger than the CD4+ population in all groups; and electroporated DNA vaccination induced the 
highest CD8+ counts [15].  All groups displayed significant protection against B. abortus 30 
days post challenge; however only the electroporated group was comparable to S19 [15, 152].  
Together, the data suggests that L9 DNA vaccination induces CD8+ mediated protection against 
B. abortus. 
RIBOSOMAL L7/L12 
 The brucella 50S ribosomal subunit L7/L12 is an immunodominant Th1 antigen in both 
cattle and mice [153, 168].  Splenocytes from mice vaccinated with Strain 19 proliferate in 
response to rL7/L12 but do not produce anti-L7/L12 antibodies [153].  CD4+ PBMCs from cattle 
vaccinated with rL7/L12 proliferate in response to recombinant L7/L12 [168], indicating that a 
cell-mediated response to this antigen is not species restricted.  Without adjuvant, rL7/L12 failed 
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to provide protection against B. abortus challenge while rL7/L12 in various adjuvants or L7/L12 
DNA vaccination has been shown to provide protection 7 to 30 days post challenge [104, 153-
155].  Specific cytotoxic CD8+ cells were present in Escheriosome rL7/L12 vaccinated mice, but 
no CD4+ cytotoxic activity was detected [153].  Splenocytes from recombinant and DNA 
vaccinated L7/L12 mice produced significant IFN-γ and TNF-α and low but significant amounts 
of IL-4 when stimulated with rL7/L12 [104, 153-155]. 
COMBINATION VACCINATION 
Immunization with multiple antigens has been shown to effectively enhance protection 
against brucellosis.  Co-administration of both recombinant and DNA vaccines of B. abortus 
BP26 and trigger factor showed greater protection than either did individually [149, 161].  It is 
also possible that co-immunization does not increase protection.  In mice, rOmp16 + rOmp19 
immunization did not significantly alter protection compared to the individual recombinant 
proteins against B. abortus challenge [41].  However, immunization with recombinant 
immunodominant regions of Omp19 and P39 enhances antibody production and protection 
against both B. abortus and B. melitensis compared to immunization with either individual 
antigen [67].  Furthermore, Omp16 co-immunized with other antigens enhances protection [104, 
169], suggesting that the proper combination of antigens is more important than simply including 
more antigens.   
 A divalent DNA vaccine encoding both L7/L12 and Omp16 induces significantly higher 
antibody titers, IFN-γ+ splenocytes, and protection against B. abortus than either univalent DNA 
vaccine [104].  Another study found an influenza viral vector expressing L7/L12 and Omp16 
provided long term protection against B. abortus and B. melitensis in both pregnant and non-
pregnant cattle [169-172].  The immune response consisted of IgG2a dominate isotype, CD4+ 
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and CD8+ cells, and IFN-γ production [169-172].  This vaccine was found to provide protection 
against abortion and heifer and fetal colonization comparable to Strain 19 [170-172].  These 
studies indicate that vaccination with the combination of L7/L12 and Omp16 is an effective way 
of increasing protection against B. abortus and B. melitensis [104, 171].   
 A combination DNA vaccine of BCSP31, SOD and L7/L12 provided significantly greater 
protection against B. abortus than the univalent DNA vaccines did in mice [100].  IFN-γ 
producing CD4+ and CD8+ cells specific to each protein were detected [100].  Protection was 
mediated primarily by CD4+ cells but was highest when both subsets were present [100].  
Further, both subsets were capable of specific cytotoxic activity, but CD8+ cells displayed higher 
activity [100]. 
 Mice co-immunized with recombinant immunodominant regions of Omp19 + P39 were 
significantly more protected from both B. abortus and B. melitensis than the univalent groups 
[67].  Sera from rOmp19 + rP39 vaccinated mice protected macrophages from cytopathic effects 
of B. abortus and B. melitensis in vitro significantly more than either recombinant antigen 
individually [67].  Splenocytes from the rOmp19 + rP39 group produced significantly higher 
levels of IFN-γ, IL-2, and IL-12 than the univalent groups; and IL-4 was not detected in any 
group.  Interestingly, the P39 group did not produce detectable IL-12 while the rOmp19 + rP39 
produced significantly more than the rOmp19 group.  This data suggests an advantage to using 
multiple antigens may result in a synergistic effect which induces cytokines an antigen normally 
would not stimulate and increases overall stimulation of the immune system [67].  In conclusion, 
this study indicates that co-immunization with regions of antigens is capable of increasing both 
protection and cross protection against Brucella species. 
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 The Brucella antigens Cu/Zn SOD, Omp19, Omp16 and L7/L12 have been shown to 
induce a strong Th1 response, cross protection and provide higher protection when co-
immunized other antigens [67, 100, 104, 145, 171].  Immunization with these antigens has also 
revealed other desirable characteristics such as mucosal immunity [39, 54], cytotoxic CD8+ 
activity [100, 153], protective antibodies [39, 67, 104], and activation of APCs [41].  The 
antigens BP26, L9, and Omp25 have not been extensively used in co-immunization studies but 
reliably provide high levels of protection [15, 64, 148-152].  Aside from inducing protection and 
a strong Th1 response, these antigens are conserved [148, 149, 160, 164], recognized in multiple 
animal species [56, 60, 101, 159, 160], induce TNF-α [15, 101, 150], and cytotoxic CD8+ 
activity [151].   
HYPOTHESES AND SPECIFIC AIMS 
 The overall goal of this project is to design a nonliving vaccine capable of inducing 
protection against B. abortus infection.  To achieve this, two DNA vaccines p425/BabV1 and 
p425/BabV2 were constructed using bioinformatics technology.  The hypothesis for this work is 
that it is possible to design a DNA vaccine recognized by the humoral immune response of 
Brucella abortus Strain 19 vaccinated goats.  To test this hypothesis, the following aims were 
pursued. 
1. The p425/BabV1 and p425/BabV2 were designed and constructed from protective 
epitopes. 
2. The p425/BabV1 and p425/BabV2 can be transfected into eukaryotic cells.   
3. The BabV1 and BabV2 genes are transcribed to RNA.   





MATERIAL AND METHODS 
ANTIGEN AND EPITOPE SELECTION 
Literature mining was performed to search for known protective antigens and epitopes 
from B. abortus.  Sequences for the antigens were obtained from NCBI Genbank [173] (Table 
2.1).  MHC II epitope selection was performed using 15mer binding data from Epimatrix [174] 
and IEDB-II [175].  MHC I data was obtained using IEDB-I and Epimatrix to search for 
nonamers [175].  The human and bovine MHC alleles used are listed in Table 2.2.  RANKPep 
was used to predict proper proteasome processing [176].  Overlapping regions of MHC I and 
MHC II binding epitopes and known protective epitopes were selected to be included in the 







Table 2.1 Protective B. abortus Antigen Accession Numbers 
Table of B. abortus protective antigens and the corresponding NCBI Genbank accession number. 
PLASMID CONSTRUCTION 
The BabV1 and BabV2 conalbumin signal sequence and open reading frames were codon 
optimized for Criteculus griseus and synthesized by Integrated DNA Technologies (IDT, 
Coralville, IA).  The BabV genes were under the control of CMV Promoter (vector pGWIZ, 
Gene Therapy Systems bp 844-899, CTC, 900-918) and contain the conalbumin signal sequence 













epitopes from SOD, L7/L12, Omp16, and Omp19 with free rotational spacers between epitopes.  
The BabV2 open reading frame contains epitopes from SOD, L9, BP26, and Omp25 with free 
rotational spacers between epitopes.  The free rotational spacers allow the protein to fold in a 
way that would produce conformational epitopes similar to the native antigen [177].  The vector 
p425 is a heavily modified pBluescript vector and was obtained from laboratory stocks.  Plasmid 
p425 contains the chicken ovalbumin polyA tail sequence (GenBank Accession #J00895 base 








Table 2.2 Selected MHC Alleles 
Table of the human MHC I and MHC II alleles and bovine MHC I alleles used to predict 
immunogenic epitopes via IEDB I, IEDB II, and Epimatrix. 
 
The pBabV1, pBabV2, and p425 plasmids were digested with Anza restriction enzymes 
BshTI and SalI (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions.  Digested 
DNA bands were extracted from a 1% agarose SYBR®Safe gel (Thermo Fisher Scientific, 
Waltham, MA) using a razor.  Agarose was dissolved and the digested DNA was concentrated 
using Zymoclean™ Gel DNA Recovery Kit (Zymo Research, Irvine, CA) according to the 
manufacturer’s directions.  Digested conalbumin signal sequence and open reading frames of 
BabV1 and BabV2 were ligated into the digested p425 using Quick Ligase™ (New England 
Human MHC 
I Alleles 




A0101 BoLA-1*01901 DRB1*0101 
A0201 BoLA-2*01201 DRB1*0301 
A0301 BoLA-4*02401 DRB1*0401 
A2402 Bola-6*01301 DRB1*0701 
B0702 BoLa-3*01701 DRB1*0801 
B4403  BoLa-2*00801 DRB1*1101 
  BoLa-2*1601 DRB1*1301 
  BoLa-1*2301 DRB1*1501 
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Biolabs, Ipswich, MA) according to kit’s recommendation to make p425/BabV1 and 























Table 2.3 List of B. abortus Epitopes Used in DNA Vaccine Construction 
Table of antigens and corresponding amino acid residues predicted to be immunogenic epitopes 
by IEDB-I, IEDB-II, Epimatrix, and RANKPep which are included in the p425/BabV1 and 
p425/BabV2 vaccines. 
 
Sequences were PCR amplified using the primer sets in Table 3.4 and AccuPrime™ 
DNA polymerase enzyme and buffer (Invitrogen, Carlsbad, CA) according to manufacturer’s 
recommendations.  Parameters for PCR were 95°C for 4 minutes then 25 cycles of 95°C for 30 
seconds, annealing temperature (Table 2.4) for 30 seconds, 68°C for 45 seconds, and a final 
extension segment of 68°C for 5 minutes was performed.  Gel electrophoresis was used to 
determine the size of the plasmids or PCR products.  Briefly, 1% agarose gels containing 
ethidium bromide were electrophoresed at 90 mA and UV translumination was used to visualize 






















undigested plasmid samples, 1 Kbp (Bayou Biolabs, Metairie, LA) and 100 bp ladders (Bayou 
Biolabs, Metairie, LA) for digested plasmids, and 100 bp ladder for PCR products.  The products 
were sequenced by GeneLab in the School of Veterinary Medicine at Louisiana State University 
using the Sanger dideoxynucleotide sequencing method. 







BabVpolyA F TAT GGG GGA AAA ATG CAG CCT 756 53 
BabVpolyA R CAA TAC GCC CGC GTT TCT T     
BabV1 F CAA GCT CAA TGG CTC CAA CG 847 51.5 
BabV1 R AGC AAT TGC CTT GTC AGC AT     
Conss1 F CGT CGT CGA CAA CAT GAA GC 804 54.8 
Conss1 R GCC CTT CTT TGA CC AAT GC     
BabV2 F CTA TGA CCG CGA ACA ACG ACG AG 843 51.5 
BabV2 R CTG GAG CAG CTT GGT CAT ACA     
Conss2 F CGT CGT CGA CAA CAT GAA GC 745 53 
Conss2 R GTT CGC GAC TGC TCG TTT G     
 
Table 2.4 BabV Primer Sets 
Table containing the primer sets used to PCR amplify and sequence the BabV1 and BabV2 genes 
in p425/BabV1 and p425/BabV2.  The primer sets were designed to overlap in a way that 
allowed the entire BabV1 and BabV2 genes to be accurately sequenced.  Sequence of the forward 
and reverse primers, predicted product size in base pairs, and annealing temperature are included.  
 
CELLS AND TRANSFECTION 
Plasmids were maintained and replicated in MAX Efficiency® Stbl2™ competent 
bacteria (Invitrogen, Carlsbad, CA) incubated at 37ºC.  Escherichia coli were transfected with 
pBabV1, pBabV2, p425/BabV1, and p425/BabV2 plasmids using the manufacturer’s directions.  
Ampicillin was used to select for transfected cells.  Plasmids were harvested using 
ZymoPURE™ Plasmid Midiprep (Zymo Research, Carlsbad, CA) or Zyppy™ Plasmid Miniprep 
(Zymo Research, Carlsbad, CA) kits according to the kit’s recommendations. 
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Recombinant proteins were expressed in a Chinese hamster ovary (CHO K1) (ATCC, 
Manassas, VA) cell line cultured in Corning® SF media (Corning Inc., Corning, NY) 
supplemented with 5% fetal bovine serum, glutamax (Gibco, Grand Island, NY), and incubated 
at 37°C with 5% CO2 and humidity.  The CHO K1 cells were grown to confluence in T150 
flasks then washed with room temperature PBS (Gibco, Grand Island, NY) then passaged using 
TrypLE™ Express (Gibco, Grand Island, NY) to disassociate and split cells according to the 
manufacturer’s directions into six well plates.  CHO K1 cells were transfected 24 hours after 
passaging with Lipofectamine™ 3000 (Thermo Fisher Scientific, Waltham, MA) according to 
the manufacturer’s instructions.  CHO K1 cells transfected with p425/BabV1 and p425/BabV2 
are referred to as CHOB1 and CHOB2, respectively.  Transfected CHO K1 cells were selected 
using media supplemented with 50 µg/ml puromycin 24 hours to allow cells to recover.  One 
week after transfection, individual clusters were picked with a sterile inoculating loop and 
transferred to individual wells.  When confluent in the wells, the cloned cells were disassociated 
with TrypLE™ Express and transferred to a T25 flask.   
When CHOB1, CHOB2, and negative control CHO K1 cells were confluent, the T25 
flasks were washed twice with PBS and cultured with Corning® SF media (Corning Inc., 
Corning, NY) supplemented with glutamax (Gibco, Grand Island, NY) and 50 µg/ml Puromycin 
(absent in negative control media) and incubated at 37°C with 5% CO2 and humidity.  After 72 
hours, media was collected and cells were washed twice with PBS.  Cells were then 
disassociated with TrypLE™ Express and collected in a 15 ml tube.  Serum free media and cell 





GENOMIC DNA EXTRACTION AND RT-PCR 
 Genomic DNA was extracted from the CHOB1, CHOB2, and negative control CHO K1 
cells using a DNEasy® Blood and Tissue Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions.  The BabV1 and BabV2 genes were PCR amplified using the primer 
sets listed below (Table 2.5).  Parameters for PCR were 95°C for 4 minutes then 30 cycles of 
95°C for 30 seconds, annealing temperature (Table 2.5) for 30 seconds, and 68°C for 25 seconds 
followed by a final extension of 68°C for 5 minutes.  The size of PCR products was determined 
via gel electrophoresis procedure as described above.  Products were sequenced by GeneLab in 
the School of Veterinary Medicine at Louisiana State University using the Sanger 
dideoxynucleotide sequencing method. 
 To determine if the BabV1 and BabV2 genes were transcribed, RNA extraction was 
performed using an RNEasy® Plus Micro Kit (QIAGEN, Hilden, Germany) according to the 
kit’s recommendations.  The RNA sample was immediately used as a template with an OneStep 
RT-PCR Kit (QIAGEN, Hilden, Germany) using the primers in Table 2.5.  The thermocycler 
parameters for reverse transcription and initial PCR activation were 50°C for 30 minutes then 
95°C for 15 minutes, respectively.  This was followed by 40 cycles of 94°C for 30 seconds, 
annealing temperature (Table 3.5) for 30 seconds, then 72°C for 1 minute and a final extension 
of 72°C for 10 minutes.  The PCR fragments were gel extracted using the Zymoclean™ Gel 
DNA Recovery Kit (Zymo Research, Irvine, CA) and sequenced by GeneLab in the School of 











CHO GADPH F CGA GAT CCC GCC AAC ATC AA 54 501 
CHO GADPH R TGT CAG ATC CAC AAC GGA CAC 54   
B1Conss F ACC GTC GTC GAC AAC ATG AAG 55 694 
B1Conss R ACT GGG GAT ATC GTT GGA GC 55   
B1BabV F TTC GAT GTT GTC CTT GCC GA 54 920 
B1BabV R GAA GGC TGC ATT TTT CCC C 54   
B2Conss F GTC GTC GAC AAC ATG AAG CTC 53 636 
B2Conss R CTC GTT GTT CGC GGT CAT AG 53   
B2BabV-1 F AAA CTA TTG GAC TCG GCC CT 54 485 
B2BabV-1 R TCC TGC AGT CAA GTA CGG C 54   
B2BabV-2 F CCT GGT GGG AGT CCT GAC AT 53 730 
B2BabV-2 R GAA TTG CAC CTG CTG TTC TCA CAG T 53   
BCHOpolyA-1 F GTC CCT TCC AAC AAG ACC CA 54 676 
BCHOpolyA-1 R TCC CTG CTA CAC AAC CTT GC 54   
BCHOpolyA-2 F CCA TTC CTA TGC TGA CAA GGC 54 688 
BCHOpolyA-2 R CTG GCA CTC TGT TAC CC 54   
 
Table 2.5 CHOB Primer Sets 
Table of primer sets used during PCR, RT-PCR, and sequencing BabV1 and BabV2 from 
genomic DNA and RNA including the 5’ to 3’ sequence of the forward and reverse primers.  The 
CHO GADPH primer set is specific to a housekeeping gene in CHO K1 cells and used as a 
positive control.  The primer sets were designed to overlap in a way that allowed the entire 
BabV1 and BabV2 genes to be accurately sequenced.  The predicted product size in base pairs 
and annealing temperature used in the PCR and RT-PCR protocols are included. 
 
SERA AND BRUCELLA ANTIGENS 
 Sera from B. abortus Strain 19 vaccinated goats was pooled from laboratory stocks 
collected from experimentally infected animals (see Appendix B) and diluted 1:7500 in 1% 
gelatin solution (TBS/Tween 20%) to make the primary antisera for use in Western blots.  The 
secondary antibody donkey anti-goat (Abcam, Cambridge, UK) was diluted 1:5000 in 1% gelatin 
solution (TBS/Tween 20%).  Acetone-killed B. abortus Strain 2308 was acquired from legacy 




WESTERN BLOT  
Cell samples were thawed and pelleted by centrifugation at 500g for 10 minutes and 
supernatant was then discarded.  Cells were resuspended in 5 ml of PBS, and cell counts were 
normalized using Volupack tubes (Techno Plastic Products, Trasadingen, Switzerland).  Equal 
numbers of cells were lysed with M-Per™ Mammalian Protein Extraction Reagent (Thermo 
Fisher Scientific, Waltham, MA) according to the manufacturer’s recommendations.  Serum-free 
media and lysate samples were stored at -20°C until testing.   
To prepare samples for Western blot, 15 µl of 2x Laemmli Sample Buffer (Sigma 
Aldrich, St. Louis, MO), 10 µl of 10x DTT and 15 µl of serum free media, cell lysate samples, or 
B. abortus Strain 2308 antigen were mixed then heated to 100ºC for 10 minutes.  The standard 
used was Precision Plus Protein™ Dual Color Standards 10-250 kDa (Bio-Rad, Hercules, CA).  
Samples were run at 70V for 10 minutes then 200V for 80 minutes in a Criterion™ Precast Gel 
(Bio-Rad, Hercules, CA).  After electrophoresis was completed, the gel was placed in transfer 
buffer (20% methanol in Tris-glycine electrode buffer) for 5 minutes to equilibrate.   
Nitrocellulose was rehydrated in transfer buffer for 30 minutes.  Electrophoretic transfer 
to the nitrocellulose was performed at 25V for 50 minutes.  The nitrocellulose membrane was 
rinsed with TBS/Tween 20% and the membrane was blocked in TBS/Tween 20% with 5% milk 
solution for 1 hour at 37°C in a shaking incubator.  The membrane was washed four times with 
TBS/Tween 20% for five minutes each wash.  Membranes were incubated with the primary 
antisera for one hour at room temperature with shaking and then rinsed in TBS/Tween 20% three 
times for five minutes per wash.  Donkey anti-goat secondary antibody diluted to 1:5000 in 1% 
gelatin TBS/Tween 20% was incubated with the membrane at room temperature for one hour 
while shaking.  The membrane was rinsed and washed with TBS/Tween 20% four times with 
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five minutes per wash then rinsed with distilled water.  The color reaction of the membrane was 
developed in 1-Step Ultra TMB-Blotting Solution (Thermo Fisher Scientific, Waltham, MA) 










































PLASMID CONSTRUCTION AND CHO K1 TRANSFECTION 
In order to confirm the plasmids were constructed properly, gel electrophoresis was used 
to determine if the plasmids, digested DNA, and PCR products matched the expected sizes.  The 
harvested p425, pBabV1, pBabV2, p425/BabV1, and p425/BabV2 plasmids matched the 
expected sizes on gel electrophoresis (Figure 3.1).  The products of BshTI and SalI digestion of 
the p425, pBabV1, and pBabV2 plasmids were the expected sizes, as well (Figure 3.2).  
BabV1/425 and BabV2/425 plasmids were PCR amplified, and the products matched the 
predicted sizes (Figure 3.3).  The PCR products were sequenced to confirm the correct sequence.  
Puromycin successfully selected for transfected CHOB1 and CHOB2 cells.  Approximately five 
colonies of CHOB1 and CHOB2 cells per well survived after introduction of 50 µg/ml 
puromycin to the media.  Replicating CHO K1 cells were observed five days post introduction of 
puromycin, and no replicating CHO K1 cells were observed in the untreated control wells. 
 
Figure 3.1. BabV Plasmid Gel Electrophoresis 
A gel electrophoresis was run on the original 7.) p425 (14,977 bp), 6.) pBabV1 (3,855 bp), and 
5.) pBabV2 (3,862 bp). 8.) supercoiled ladder.  The p425 with the BabV1 and BabV2 inserts are 





 Figure 3.2.  BabV SalI and BstHI Digested Samples 
A gel electrophoresis was run on the undigested 10.) pBabV2, 12.) pBabV1, and 14.) p425 and 
their digestion products with a 15.) 1 Kbp ladder.  The restriction enzymes SalI and BstHI were 
used to extract the BabV1 and BabV2 inserts from the plasmids and prepare p425 for ligation. 
The 11.) BabV1 (1,076 bp) or 9.) BabV2 (1,103 bp) inserts were ligated into digested 13.) p425 
(14,179 bp) to make 6 and 8.) p425/BabV1 and 2 and 4.) p425/BabV1, respectively.  The 
completed 5 and 7.) p425/BabV1 (14,179 and 1,076 bp bands) and 1 and 3.) p425/BabV2 
(14,179 and 1,103 bp bands) were digested again to confirm the inserts were present. 
 
 
Figure 3.3.  BabV PCR Gel Electrophoresis 
A gel electrophoresis was run on PCR products with a 7.) 100 bp ladder.  The entire BabV1 and 
BabV2 were PCR amplified from p425/BabV1 and p425/BabV2 respectively with three primer 
sets per plasmid.  These products were sequenced to confirm the expected sequence.  The 
products of PCR with template p425/BabV2 and primer set 1.) BabVpolyA (756 bp), 2.) BabV2 
(843 bp), and 3.) Conss2 (745 bp).  The products of PCR template p425/BabV1 and primer set 
4.) BabVpolyA (756 bp), 5.) BabV1 (847 bp), and 6.) Conss1 (804 bp).   
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GENOMIC DNA PCR AND SEQUENCING 
 The gCHOB1, gCHOB2 and negative control gCHO K1 templates, but not the 
p425/BabV1 and p425/BabV2 plasmids, produced bands of the predicted sizes when PCR 
amplified using the CHO GADPH primer set (Figure 3.4 and Figure 3.5).  This primer set is 
specific to a house keeping gene in the CHO K1 cells and used as a positive control.  Genomic 
CHOB1 and plasmid p425/BabV1 templates produced bands of the estimated size when PCR 
amplified using the B1BabV primer set (Figure 3.6).  The primer sets B1Conss, BCHOpolyA-1, 
and BCHOpolyA-2 produced bands of the predicted sizes using gCHOB1 as the template (Figure 
3.7).  Similarly, gCHOB2 template produced bands of the appropriate size with the B2BabV-1 
primer set (Figure 3.6).  When gCHOB2 template was used, bands of the predicted base pair 
length were produced by the B2Conss, B2BabV-2, BCHOpolyA-1, and BCHOpolyA-2 primer 
sets (Figure 3.8).  No bands were produced by the gCHO K1 with primer sets above.  The PCR 
products were successfully gel extracted and confirmed to contain the expected sequence via 
Sanger dideoxynucleotide sequencing reaction.  
 
 
Figure 3.4 CHOB2 Genome PCR 1 
A gel electrophoresis was run on PCR products with a 100 bp ladder (5).  The GADPH primer 
set (501 bp) was used as a positive control to confirm extraction of 1-2.) gCHOB2 DNA and 3.) 




Figure 3.5 CHOB1 Genome PCR 1 
A gel electrophoresis was run on PCR products with a 100 bp ladder (7).  The GADPH primer 
set (501 bp) was used as a positive control to confirm extraction of 2.) gCHOB1 DNA and 4.) 
gCHO K1.  6.) Plasmid p425/BabV1 was used as the negative control for the GADPH primer 
set.  The products of the PCR reaction between primer set B1BabV (920 bp) of 1.) gCHOB1 and 
3.) gCHO K1 DNA.  The negative control for this primer set was 5.) p425/BabV1.   
 
 
Figure 3.6 CHOB1 and CHOB2 Genome PCR 
A gel electrophoresis was run on PCR products with a 13.) 100 bp ladder.  The PCR between 
primer set B2BabV-1 (485 bp) and templates 1-5.) gCHOB2 and the positive control 7.) 
p425/BabV2 indicates the presence of the BabV2 open reading frame.  The negative control 6.) 
gCHO K1 for this reaction did not result in a product.  The PCR between primer set B1BabV 
(920 bp) and templates 9-10.) gCHOB1 and the positive control 12.) p425/BabV1 indicates the 
presence of the BabV1 open reading frame.  The negative control 11.) gCHO K1 for this reaction 




Figure 3.7 CHOB1 Genome PCR 2 
A gel electrophoresis was run on PCR products with a 12.) 100 bp ladder.  The polyA tail of 
BabV1 was confirmed to be present in gCHOB1 using primer sets 1.) BCHOpolyA-2 (688 bp) 
and 2.) BCHOpolyA-1 (676 bp).  The conalbumin signal was confirmed to be present in 
gCHOB1 with the primer set 3.) B1Conss (694 bp).  The positive control p425/BabV1 for these 
primer sets 5-7.) resulted in products of the expected sizes while the 9-11.) negative control 
gCHO K1 DNA did not result in products.  Lanes 4.) and 8.) were intentionally left blank.  
 
 
Figure 3.8 CHOB2 Genome PCR 2 
A gel electrophoresis was run on PCR products with a 15.) 100 bp ladder.  The polyA tail of 
BabV2 was confirmed to be present in gCHOB1 using primer sets 1.) BCHOpolyA-2 (688 bp) 
and 2.) BCHOpolyA-1 (676 bp).  The BabV2 open reading frame and conalbumin signal were 
confirmed to be present in gCHOB2 with the primer sets 3.) B2BabV-2 (730 bp) and 4.) 
B2Conss (636 bp).  The positive control p425/BabV2 for these primer sets 6-9.) resulted in 
products of the expected sizes while the negative control 11-14.) gCHO K1 DNA did not result 




RT-PCR was used to determine if the BabV1 and BabV2 genes were transcribed to RNA.  
The RT-PCR using B1BabV and B2BabV-1 primer sets resulted in products of the expected 
sizes in multiple CHOB1 and CHOB2 RNA templates, respectively (Figure 3.9).  The RNA 
template from CHOB1 and CHOB2 cells produced bands of the appropriate number of base pairs 
with both the CHO GADPH and BCHOpolyA-1 primer sets (Figure 3.10).  Furthermore, 
CHOB2 RNA produced a band of the predicted size with the B2BabV-2 primer set (Figure 3.11).  
The CHO K1 RNA template only produced a band with the CHO GADPH primer set (Figure 
3.9, Figure 3.10, and Figure 3.11).  Sequencing data confirmed the PCR products contain the 
expected sequences.   
 
Figure 3.9 B1BabV and B2BabV-1 RT-PCR on CHOB1 and CHOB2 RNA 
A gel electrophoresis was run on RT-PCR products with a 15.) 100 bp ladder.  Wells 1-5 are the 
products of an RT-PCR with the primer set B2BabV-1 (485 bp) and RNA from multiple CHOB2 
cultures. Wells 6-10 are the products of primer set B1BabV (920 bp) and CHOB1 RNA 
templates.  This indicates that the open reading frames from BabV1 and BabV2 were transcribed 
to RNA in the CHOB1 and CHOB2 cells respectively.  Lane 11.) was intentionally left blank.  
No product was produced by the RT-PCR between negative control CHO K1 RNA and primer 
set 12.) B2BabV-1 and 13.) B1BabV.  The positive control primer set 14.) CHO GADPH (501 






Figure 3.10 BCHOpolyA-1 RT-PCR on CHOB1 and CHOB2 RNA 
A gel electrophoresis was run on RT-PCR products with a 7.) 100 bp ladder.  The CHO GADPH 
(501 bp) primer set was used as a positive control to confirm RNA was extracted from 2.) 
CHOB2, 4.) CHOB1, and 6.) CHO K1.  The RT-PCR with primer set BCHOpolyA-1 (676 bp) 
indicates RNA from the polyA tail of BabV1 and BabV2 is transcribed in the 3.) CHOB1 and 1.) 
CHOB2 cells respectively. There was no product in the RT-PCR between negative control CHO 
K1 RNA and 5.) BCHOpolyA-1. 
 
 
Figure 3.11 B2BabV2 RT-PCR on CHOB2 RNA 
A gel electrophoresis was run on RT-PCR products with a 7.) 100 bp ladder.  The CHO GADPH 
(501 bp) primer set was used as a positive control to confirm RNA was extracted from 3.) 
CHOB2 and 6.) CHO K1.  The RT-PCR between CHOB2 RNA and primer sets 1.) B2BabV-2 
(730 bp) and 2.) B2BabV-1 (485 bp) indicates RNA from the open reading frame of BabV2 was 
transcribed.  There was no product in the RT-PCR between negative control CHO K1 RNA and 




 Western blots were performed to determine if the rBabV1 and rBabV2 proteins were 
translated and recognized by the humoral immune response of B. abortus Strain 19 vaccinated 
goats.  The Western blot detected bands at approximately 60 kDa in CHO K1, CHOB1, and 
CHOB2 serum-free media samples (Figure 3.12).  Bands of varying molecular weights were 
detected in the B. abortus Strain 2308 antigen sample (Figure 3.12).  Unique bands were not 
detected in the CHOB1 and CHOB2 samples as compared to the negative control CHO K1 
media samples (Figure 3.12).  The Western blot using CHOB1, CHOB2, or CHO K1 samples 
cell lysate samples did not detect bands (Figure 3.13).  Similar to the previous Western blot, 
multiple bands were detected in the positive control B. abortus Strain 2308 antigen (Figure 3.13). 
 
Figure 3.12 Western Blot on Serum Free Media Samples  
A Western blot using 1:7500 dilution of sera pooled from B. abortus Strain 19 vaccinated goats 
as the primary antibody.  Standards are were run in lanes 2.) and 11.).  The positive control 1.) 
killed B. abortus Strain 2308 antigen indicates the primary antisera is able to detect multiple B. 
abortus antigens.  Serum free media cultured with non-transfected CHO K1 cells for 72 hours 
was used as the negative control (lanes 3. and 12.).  The rBabV1 (31 kDa) and rBabV2 (32 kDa) 
was not detected in the 5-10.) CHOB1 and 13-18.) CHOB2 serum free media respectively.  Lane 






Figure 3.13 Western Blot on Cell Lysates 
A Western blot using 1:7500 dilution of sera pooled from B. abortus Strain 19 vaccinated goats 
as the primary antibody.  Standards are in lanes 2.) and 13.).   The positive control 1.) killed B. 
abortus Strain 2308 antigen indicates the primary antisera detected multiple B. abortus antigens.  
Cell lysate from non-transfected CHO K1 cells was used as the negative control 3.) and 12.).  
The rBabV1 (31 kDa) and rBabV2 (32 kDa) was not detected in the lanes 5-10.) CHOB1 or 14-
18.) CHOB2 cell lysates respectively.  Lane 4.) was intentionally left blank. 
 
DISCUSSION  
Brucellosis is a widespread zoonotic disease which causes economic burdens due to 
reproductive losses in animals [2, 13].  The current live-attenuated B. abortus vaccines do not 
meet the criteria for an ideal vaccine [11, 69, 70, 73] .  The goal of this project was to determine 
if it is possible to design safe, nonliving vaccines that induce protection against B. abortus.  The 
method of DNA vaccination was chosen because it is suited for inducing a cell-mediated 
immune response, primarily Th1 which is required for resistance to brucellosis [5, 15, 17, 35-38, 
85, 86].  Two plasmids were constructed using epitopes from cellular associated antigens known 
to induce protection against B. abortus (Table 1.1).  These plasmids were transfected into CHO 
K1 cells, and selected under puromycin pressure.  The PCR on genomic DNA indicated the 
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p425/BabV1 and p425/BabV2 plasmids were successfully transfected into CHOB1 and CHOB2 
cells, respectively (Figure 3.4, Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8).  The RT-PCR 
products and corresponding sequence data indicated the BabV1 and BabV2 genes were faithfully 
transcribed to RNA within the CHOB1 and CHOB2 cells, respectively (Figure 3.9, Figure 3.10, 
and Figure 3.11).  However, Western blots using pooled B. abortus Strain 19 vaccinated goat 
sera as the primary antibody did not detect the rBabV1 or rBabV2 proteins either in the media or 
cell lysates (Figure 3.12 and Figure 3.13). 
The pBabV1, pBabV2, and p425 plasmids were successfully digested indicating the 
presence of the BshTI and SalI restriction enzyme sites (Figure 3.2).  The approximately 1,000 
bp bands from digested pBabV1 and pBabV2 and the approximately 14,000 bp band from 
digested p425 were extracted and purified from the SYBR®Safe gel.  These digested fragments 
contained a conalbumin signal sequence and BabV open reading frame.  The fragments were 
ligated into the digested p425 which contained the 3’ chicken ovalbumin polyA tail to complete 
the BabV1 and BabV2 genes.  The newly constructed plasmids p425/BabV1 and p425/BabV2 
were shown by gel electrophoresis to be the expected sizes of 15,277 bp and 15,250 bp, 
respectively (Figure 3.1).  PCR reactions were performed to amplify the inserted region and 
polyA tail using three primer sets per plasmid (Table 2.4).  The PCR products matched the 
expected sizes, and the successful reaction indicated primer binding sites from both the BabV 
genes and p425 were present in p425/BabV1 and p425/BabV2 (Figure 3.3).  The PCR products 
were sequenced, confirming the expected sequence of p425/BabV1 and p425/BabV2, which 
includes the conalbumin signal sequence, open reading frames, and chicken ovalbumin polyA 
tail.  The plasmids were then transfected into CHO K1 cells.   
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 Following the introduction of 50 µg/ml puromycin to the culture media, approximately 
five colonies of CHOB1 and CHOB2 cells survived per well.  This indicates that the 
concentration of puromycin used is toxic to CHO K1 cells.  At five days after the transfection 
procedure, replicating cells were observed in the CHOB1 and CHOB2 wells but not in the 
untreated control wells.  Taken together, this indicates that the puromycin successfully selected 
for transfected cells expressing the puromycin resistance gene in p425/BabV1 and p425/BabV2.   
The positive control, CHO GADPH, PCR indicated genomic DNA was successfully 
extracted from CHOB1, CHOB2, and CHO K1 cells (Figure 3.4 and Figure 3.5).  Sequencing 
data from PCR products in Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8 confirmed the 
conalbumin signal sequence, BabV open reading frame, and polyA tail sequence from 
p425/BabV1 and p425/BabV2 were present in gCHOB1 and gCHOB2 DNA, respectively.  
These products were not present when the negative control, gCHO K1 DNA, was used as the 
template, indicating the control cells were not contaminated.   
 To determine if the vaccine sequences were being transcribed, RT-PCR was used to 
detect BabV1 and BabV2 RNA in the CHOB1 and CHOB2 cells, respectively.  The RT-PCR 
products from the CHO GADPH primer set reactions with CHOB1, CHOB2, and CHO K1 
indicates RNA was successfully extracted from all cultures (Figure 3.9 and Figure 3.10).  The 
products in Figure 3.9, Figure 3.10 and Figure 3.11 indicate RNA from within the BabV open 
reading frame and polyA tail were transcribed in multiple CHOB1 and CHOB2 cell cultures but 
not the negative control CHO K1 cells.  Sequencing data confirmed the RT-PCR products 
contained the expected sequences.  Taken together, these data indicate the BabV open reading 
frame and polyA tail from the BabV1 and BabV2 genes were faithfully transcribed to RNA in the 
CHOB1 and CHOB2 cells, respectively. 
45 
 
The BabV1 and BabV2 genes contain the conalbumin signal sequence which directs 
recombinant proteins to be secreted when expressed in eukaryotic cells [177].  However, no 
unique bands were detected using Western blots in the CHOB1 and CHOB2 media compared to 
the CHO K1 media (Figure 3.12).  Multiple bands were detected by the Western blots in the 
positive control, indicating the primary antiserum is capable of detecting B. abortus Strain 2308 
antigens.  It is possible the proteins are not being secreted despite the secretion signal.  In order 
to test for this, cells were lysed to extract endogenous proteins for analysis.   
A Western blot was performed on cell lysates to determine if the rBabV proteins were 
present within the CHOB1 and CHOB2 cells; however, no bands were detected in the CHOB1, 
CHOB2, or CHO K1 samples (Figure 3.13).  The rBabV proteins should not have been degraded 
after lysis because a protease inhibitor cocktail was included in the lysis buffer.  However, the 
possibility of the proteins being secreted cannot be ruled out.  If this is the case, the 
concentration of endogenous protein may be below the detectable limits. 
It is possible that the concentration of the recombinant proteins in the media and cell 
lysates was below the detectable limits of the Western blot.  This may be overcome by 
concentrating the media and cell lysate samples.  Alternatively, increasing the concentration of 
the primary antisera may detect the protein at lower concentrations.  The concentration of protein 
in the samples may be low due to low expression levels of the BabV1 and BabV2 genes.  The 
RT-PCR used in this study only detected the presence of RNA and not expression levels.  A 
qPCR would be able to determine the expression levels of the BabV1 and BabV2 genes.  In 
addition, transfecting a different cell line could increase expression of the proteins.   
A limitation of Western blots is the requirement for antibodies that bind to linear 
epitopes, which are produced far less than antibodies which bind to conformational epitopes 
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[178, 179].  Therefore, using a method which recognizes conformational epitopes, such as 
ELISA, may detect the rBabV proteins.  It has been reported that the brucella antigens Omp25 
and BP26 can be detected by both ELISA and Western blots using serum from naturally infected 
or vaccinated animals [101, 180-182].  However, a study using anti-BP26 mAbs indicates ELISA 
and Western blot methods are capable of detecting different epitopes [183].  Studies indicate sera 
from several animal species that were naturally infected or vaccinated detects Cu/Zn SOD via 
Western blot [143, 180, 184, 185].  However, serum from B. abortus infected and Strain 19 
vaccinated cows does not detect Cu/Zn SOD via ELISA [122].  This indicates several of the 
antigens used to construct p425/BabV1 and p425/BabV2 contain epitopes detectable by ELISA 
which cannot be detected via Western blot.  
In this study, Strain 19 vaccinated goat sera was used as the primary antibody for the 
Western blots in order to determine if the BabV vaccines were recgonized by the humoral 
response of a known effective vaccine.  However, using sera from animals naturally or 
experimentally infected with a virulent strain may be more suitable for detecting the rBabV1 and 
rBabV2 proteins.  It is known that the antigens recognized by serum from vaccinated and 
naturally infected animals differ [186].  Serum from bovines vaccinated with Strain 19 does not 
detect BP26 via Western blot or ELISA [60, 187].  Further, Rev 1. and M5-90 vaccinated sheep 
produce no or low levels of anti-BP26 antibodies [160, 188].  However, sera from naturally 
infected animals detect BP26 via both Western blot and ELISA [160, 188, 189].  Taken together, 
this suggests that the rBabV1 and rBabV2 proteins may contain epitopes recognized by antisera 
from animals infected with a virulent Brucella spp. but not vaccinated animals.  
Sera from Strain 19 vaccinated goats was chosen because polyclonal antibodies binding 
to several epitopes would increase the chance of detection over a monoclonal antibody that only 
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binds to a single epitope which may not be present in the rBabV proteins.  Brucella-infected 
sheep sera and murine monoclonal antibodies recognize the BP26 linear epitopes 93-101 and 
104-111, which are not present in rBabV2 (Table 2.3) [183].  Furthermore, BP26 amino acids 
230-250 have been reported to not be detected by Western blot using sera from B. melitensis and 
B. ovis infected sheep [182].  Future research could insert an epitope into the BabV1 and BabV2 
genes which binds to a known monoclonal antibody. This could serve as a marker for detecting 
the recombinant proteins via Western blot or ELISA.  
Another possible reason the Western blots did not detect the recombinant proteins is the 
humoral immune response may not be suitable for detecting the rBabV1 and rBabV2.  Cell-
mediated immunity is crucial to protection against brucellosis [5, 17, 35-38].  For this reason, T 
cell epitopes were selected and B cell epitopes were not intentionally included in the project 
design.  The vaccines may not contain epitopes recognized by the humoral response.  If this is 
the case, the cell-mediated immune response would be more likely to detect the rBabV1 and 
rBabV2 proteins.  Numerous methods have been developed to detect T cell responses to brucella 
antigens.  In delayed type hypersensitivity tests, brucella antigen is injected into the skin of 
vaccinated or naturally infected animals [40, 190].  If the antigen is recognized by T cells, 
inflammation occurs at the site of injection.  Alternatively, splenocytes, lymph node tissue, and 
PBMCs from vaccinated or infected animals can be stimulated with the antigen of interest [39, 
53, 67, 87, 122, 143, 144, 160, 168].  This assay has the advantage of measuring proliferation 







SUMMARY AND CONCLUSION 
SUMMARY 
 Brucella is a genus of Gram negative, facultative intracellular pathogens which infect 
500,000 people each year globally and causes severe economic burdens in developing countries 
[1, 2, 12, 13].  The most effective means of controlling brucellosis is vaccination of animals [14, 
15].  Live-attenuated vaccines, such as B. abortus Strain 19 and RB51, are used to effectively 
control brucellosis in cattle [5, 14].  However, these vaccines are not ideal due to residual 
virulence in humans, ability to cause abortion in pregnant cattle, and serological interference 
with diagnostic tests [14].  Multiple vaccination strategies have been researched to overcome 
these issues. 
 For a vaccine to be effective against brucella infection a cell-mediated vaccine is needed. 
It has been reported that the Th1 immune response must be induced for protection [5, 17, 35-38].  
Cytotoxic CD8+ cells are also known to play a role in protective immunity [5, 40].  Heat-killed 
and recombinant brucella antigens induce lower protection and a Th2 predominant immune 
response [84, 85].  Multiple studies have found DNA vaccination with plasmids encoding 
brucella antigens to be a promising immunization strategy [15, 87, 88, 94, 100-108].  In DNA 
vaccination, a plasmid encoding the desired antigen is injected into the host, enters the host cell 
and is expressed endogenously and secreted from the cell [85, 86].  This allows multiple arms of 
the immune system to be induced, such as Th1, Th2, and cytotoxic CD8+ cells, against the 
expressed antigens [85, 87, 88].  DNA vaccination is considered to be a safer alternative for 
brucellosis vaccination [15].  Furthermore, including multiple antigens or epitopes in a vaccine 





The goal of this research project was to determine if it is possible to design safe, 
nonliving vaccines that induce protection against B. abortus.  Literature mining was performed 
to find known protective antigens.  Bioinformatic technologies were used to identify the regions 
within these protective antigens most likely to elicit a protective immune response.  The DNA 
sequence of these regions was used to construct two plasmids for DNA vaccination.  
The p425/BabV1 and p425/BabV2 plasmids were transfected into CHO K1 cells and 
expressed in order to collect the recombinant protein for analysis.  The genome of the transfected 
CHOB1 and CHOB2 cells was analyzed using PCR.  Transcription of the BabV1 and BabV2 
genes to RNA was analyzed using RT-PCR.  Finally, the media and cell lysates from transfected 
cells were analyzed via Western blot using pooled sera from B. abortus Strain 19 vaccinated 
goats.   
The PCR and RT-PCR confirmed the CHOB1 and CHOB2 cells were transfected with 
and transcribed RNA from the p425/BabV1 and p425/BabV2 plasmids, respectively.  However, 
the Western blots did not detect rBabV1 or rBabV2 in the media or cell lysate.  The antisera used 
contains antibodies specific for brucella antigens and should bind to the recombinant BabV 
proteins if an epitope is recognized by the humoral immune response of B. abortus Strain 19 
vaccinated goats.  No protein was detected in the 31 kDa or 32 kDa range for rBabV1 or 
rBabV2, respectively.  It is possible that the Western blot procedure did not detect the proteins 
due to low protein concentration or the primary antisera not recognizing the rBabV1 or rBabV2 
proteins.  Future studies will need to concentrate the protein, use different antisera, or utilize 
ELISA.  Another possible route is to use assays which detect cell-mediated immune responses 





Anza Restriction Digest (Thermofisher Scientific) Citation [191]  
1. Prepare a reaction mix by adding reagents in the order indicated in Table 1. 
2. Incubate at 37°C for 15 minutes. 








Nuclease-free water As required to make up 
final reaction volume 
 
 
Anza 10x Buffer or Anza 10X Red Buffer 2 μL 2 μL 3 μL 
DNA 0.2–1 μg 0.2–1 μg 0.2–1 μg 
Anza restriction enzyme 1 1 μL 1 μL 1 μL 
 
 
Anza restriction enzyme 2 — 1 μL 1 μL 
 
 
Anza restriction enzyme 3 — — 1 μL 
 
 
Final reaction volume 20 μL 20 μL 30 μL 
 
 








1 enzyme 2 enzyme 3 enzyme 
reaction reaction reaction 
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Zymoclean™ Gel DNA Recovery Kit (Zymo Research) Citation [192] 
1. Excise the DNA fragment1 from the agarose gel using a razor blade, scalpel or other 
device and transfer it into a 1.5 ml microcentrifuge tube. 
2. Add 3 volumes of ADB to each volume of agarose excised from the gel (e.g. for 100 µl 
(mg) of agarose gel slice add 300 µl of ADB).  Incubate at 37-55 °C for 5-10 minutes 
until the gel slice is completely dissolved2. 
3. For DNA fragments > 8 kb, following the incubation step, add one additional volume 
(equal to that of the gel slice) of water to the mixture for better DNA recovery (e.g., 100 
µl agarose, 300 µl ADB, and 100 µl water). 
4. Transfer the melted agarose solution to a Zymo-Spin™ Column in a Collection Tube. 
5. Centrifuge for 30-60 seconds.  Discard the flow-through3. 
6. Add 200 µl of DNA Wash Buffer to the column and centrifuge for 30 seconds.  Discard 
the flow-through.  Repeat the wash step. 
7. Add ≥ 6 µl DNA Elution Buffer4 or water5 directly to the column matrix. Place column 
into a 1.5 ml tube and centrifuge for 30-60 seconds to elute DNA.  Ultra-pure DNA is 









Quick Ligase™ (New England Biolabs) Citation [193] 
1. Set up the following reaction in a microcentrifuge tube on ice.  
(T7 DNA Ligase should be added last. Note that the table shows a ligation using a molar ratio of 
1:3 vector to insert for the indicated DNA sizes.)  
Use NEBiocalculator to calculate molar ratios.  
 COMPONENT  20 μl REACTION 
 Quick Ligase Reaction Buffer (2X)*  10 µl 
 Vector DNA (4 kb)  50 ng (0.020 pmol) 
 Insert DNA (1 kb)  37.5 ng (0.060 pmol) 
 Nuclease-free Water  to 20 µl 
 Quick Ligase  1 µl 
    *The Quick Ligase Reaction Buffer should be thawed and resuspended at room temperature. 
2. Gently mix the reaction by pipetting up and down and microfuge briefly. 
3. Incubate at room temperature (25°C) for 5 minutes. 
4. Chill on ice and transform 1-5 µl of the reaction into 50 µl competent cells. Alternatively, 
Store at -20°C. 











AccuPrime™ DNA polymerase enzyme and buffer (Thermofisher Scientific) Citation [194] 
Add the following components to a DNase/RNase-free, thin-walled PCR tube. For 
multiple reactions, prepare a master mix of common components to minimize reagent loss and 
enable accurate pipetting. 
 Component 
Amount for one 50-µL 
reaction 





 10X AccuPrime™ 
PCR Buffer I 
5 µL — 
 10X AccuPrime™ 
PCR Buffer II 
— 5 µL 
 Sense primer (10 
µM) 
1 µL 1 µL 
       
 Anti-sense primer 
(10 µM) 
1 µL 1 µL 
       
 Template DNA 0.1 pg to 20 ng 
10 pg to 
500 ng 
       
 AccuPrime™ Taq 
DNA 0.2 µL 0.2 µL  
Polymerase, High 
Fidelity  
     
 Autoclaved, distilled 
water 
to 50 µL to 50 µL 
       
2. Cap the tube, tap gently to mix, then centrifuge briefly to collect the contents. 
3. Place the tube in the thermal cycler, then run the following program: 




15 seconds to 2 
minutes 
25–35 cycles of:     
      
Denature 94°C 15–30 seconds 
      
Anneal 52–64°C 15–30 seconds 
      
Extend 68°C 1 minute per kb 
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4. Maintain the reactions at 4°C after cycling. Samples can be stored at –20°C until use. 




























Invitrogen MAX Efficiency® Stbl2™ Competent cells (Thermofisher Scientific) Citation 
[195]  
 
1. Thaw competent cells on wet ice. Place the required number of 17 × 100 mm Falcon® 
2059 tubes or similarly shaped polypropylene tubes (see the following note) on ice. 
2. Gently mix the cells, then aliquot 100 μL of competent cells into chilled tubes. 
3. Refreeze any unused cells in the dry ice/ethanol bath for 5 minutes before returning 
them to the −85°C to −68°C freezer. Do not use liquid nitrogen. 
4. To determine transformation efficiency, add 5 μL (50 pg) control DNA to one tube 
containing 100 μL competent cells. Move the pipette through the cells while dispensing. 
Gently tap the tube to mix. 
5. For DNA from ligation reactions, dilute the reactions 5-fold in 10 mM Tris-HCl (pH 
7.5) and 1 mM EDTA. Add 1 μL of the dilution to the cells (1–10 ng DNA), moving the 
pipette through the cells while dispensing the dilution. Gently tap the tubes to mix. 
6. Incubate the cells on ice for 30 minutes. 
7. Heat-shock the cells 25 seconds in a 42°C water bath; do not shake the cells. 
8. Place on the cells ice for 2 minutes. 
9. Add 0.9 mL of room-temperature S.O.C. Medium (Cat. no. 15544-034). 








ZymoPURE™ Plasmid Midiprep (Zymo Research) Citation [196] 
1. Add 8 ml of ZymoPURE™ P1 (Red) to the bacterial cell pellet and resuspend completely 
by vortexing or pipetting. 
2. Add 8 ml of ZymoPURE™ P2 (Green) and immediately mix by gently inverting the tube 
6 times. Do not vortex! Let sit at room temperature for 2-3 minutes. Cells are completely 
lysed when the solution appears clear, purple, and viscous. 
3. Add 8 ml of ZymoPURE™ P3 (Yellow) and mix gently but thoroughly by inversion. Do 
not vortex! The sample will turn yellow when the neutralization is complete and a 
yellowish precipitate will form. 
4. Ensure the plug is attached to the Luer Lock at the bottom of the ZymoPURE™Syringe 
Filter. Place the syringe filter upright in a tube rack and load the lysate into the 
ZymoPURE™Syringe Filter and wait 5 - 8 minutes for the precipitate to float to the top. 
5. Remove the Luer Lock plug from the bottom of the syringe and place it into a clean 50 
ml conical tube. Place the plunger in the syringe and push the solution through the 
ZymoPURE™Syringe Filter to clear the debris. Save the cleared lysate! 
6. Add 8 ml ZymoPURE™Binding Buffer to the cleared lysate from step 6 and mix 
thoroughly by inverting the capped tube 8 times.  
Vacuum Protocol 
The vacuum pump should be a 
single 
or double-staged unit capable of 
producing up to 400 mm Hg 
pressure. 
Centrifugation protocol 
A swinging bucket rotor is required for 
centrifugation. 
8. Ensure the connections of the 
Zymo-Spin™ III-P Column 
8. Remove the 50 ml Reservoir from the top of 
the Zymo-Spin™III-P Column Assembly. Ensure 
the connection between the 15 ml Conical 
Reservoir and Zymo- Spin™ III-P colum nis 
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Assembly are finger-tight and 
place onto a vacuum manifold. 
9. Add the entire mixture from 
step 7 into the Zymo-Spin™ III-P 
Column Assembly, and then turn 
on the vacuum until all of the 
liquid has passed completely 
through the column. 
10. Unscrew the purple Luer Lock 
cap from the top of the Zymo-
Spin™ III-P Column and discard 
the Reservoirs. 
finger-tight and place the assembly into a 50 ml 
conical tube. 
9. Add 10 ml of the mixture from step 7 into the 
15 ml Conical Reservoir/Zymo-Spin™ III-P 
Column assembly, and centrifuge at 500 x g for 2 
minutes. 
10. Empty the 50 ml conical tube and repeat step 
9 until the entire sample has passed through the 
column. 
Note: Steps 11-12 can also be completed using a microcentrifuge instead of the vacuum manifold 
(see full instruction manual). 
11. With the vacuum off, add 800 µl of ZymoPURE™Wash 1 to the Zymo-Spin™III-P 
Column.Turn on the vacuum until all of the liquid has passed completely through the 
column. 
12. With the vacuum off, add 800 µl of ZymoPURE™Wash 2to the Zymo-Spin™III-P 
Column. Turn on the vacuum until all of the liquid has passed completely through the 
column. Repeat this wash step. 
13. Place the Zymo-Spin™III-P Column in a Collection Tube and transfer to a 
microcentrifuge. Centrifuge at ≥10,000 x gfor 1 minute in order to remove any residual 
wash buffer.  Transfer the Zymo-Spin™III-P Column into a clean 1.5 ml tube and add 
200 µl of ZymoPURE™Elution Buffer directly to the column matrix. Incubate at room 








 Zyppy™ Plasmid Miniprep (Zymo Research) Citation [197] 
1. Add 600 µl of bacterial culture grown in LB medium to a 1.5 ml microcentrifuge tube. 
2. Add 100 µl of 7X Lysis Buffer (Blue) and mix by inverting the tube 4-6 times.  Proceed 
to step 3 within 2 minutes. 
3. Add 350 µl of cold Neutralization Buffer (Yellow) and mix thoroughly.  Invert the 
sample an additional 2-3 times to ensure complete neutralization. 
4. Centrifuge at 11,000 – 16,000 x g for 2-4 minutes. 
5. Transfer the supernatant (~900 µl) into the provided Zymo-Spin™ IIN column.  Avoid 
disturbing the cell debris pellet. 
6. Place the column into a Collection Tube and centrifuge for 15 seconds. 
7. Discard the flow-through and place the column back into the same Collection Tube. 
8. Add 200 µl of Endo-Wash Buffer to the column.  Centrifuge for 30 seconds. 
9. Add 400 µl of Zyppy™ Wash Buffer to the column.  Centrifuge for 1 minute. 
10. Transfer the column into a clean 1.5 ml microcentrifuge tube then add 30 µl of Zyppy™ 
Elution Buffer directly to the column matrix and let stand for one minute at room 
temperature. 








TrypLE™ Express (Thermo Fisher Scientific) Citation [198] 
1. Pre-warmed TrypLE™ and complete growth medium to 37°C before use. Minimize dwell 
time. 
Note: TrypLE™ may be used at ambient room temperature for many types of cells. 
2. Aspirated spent medium and discarded. 
3. Washed cell monolayer with 5 mL of Dulbecco’s Phosphate Buffered Saline (DPBS) without 
calcium and magnesium. Aspirated and discarded. 
4. Added 0.5 ml or 1 ml of TrypLE™ to well or flask, respectively.  Ensure complete coverage 
of cell monolayer with TrypLE™. 
5. Incubated at 37°C until cells have detached. Observe cell monolayer using an inverted 
microscope to ensure complete cell detachment from the surface of the flask. Gently tap flask to 
dislodge cells if necessary. 
6. Added 5–10 mL of pre-warmed complete medium to flask. Tilt flask in all directions to 
thoroughly rinse flask. Transfer cell suspension to a 15-mL conical tube. 
7. Centrifuged at 100 × g for 5–10 minutes. 
8. Discarded supernatant and resuspended cell pellet with 2–5 mL of pre-warmed complete 
medium. 








Lipofectamine™ 3000 (Thermo Fisher Scientific) Citation [199] 
Concentration of plasmid DNA: 
BabV1/425 = 1928 ng/µl  
BabV2/425 = 2794 ng/µl 
Transfection procedure: 
1. 3 six well plates were obtained.  Labeled CNTL, B1 or B2.  
2. CHO K1 cells were split using TrypLE™ and aliquoted into the wells of the plate 
3. Cells grown to 70-90% confluency 
4. Cells were washed and fed with SF media + 3% FBS + Glutamax before transfection 
Per plate: 
5. 375 µl of SF media + Glutamax mixed with 11.25 or 22.5 µl of lipofectamine 3000. 
Vortexed briefly  
6. 750 µl of SF media + Glutamax mixed with 15 µg DNA (7.5 µl BabV1/425 or 5.4 µl 
BabV2/425) and 30 µl P3000 reagent. Vortexed 
7. High and low concentrations were made by mixing 1:1 ratio of the lipofectamine and 
DNA mixtures. 
8. Mixture incubated for 10-15 minutes 
9. Cells were washed then fed with 250 µl of the final mixture 
10. Incubated for 4 days then washed, fed and analyzed for transfection success 





M-Per Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) [200]  
Prior to the procedure, 250 µl of M250 Protease Inhibitor Cocktail, Mamalian (Amresco, 
Solon, Ohio) was added to 25 ml M-Per Reagent. 
1. Thaw and pellet the cells by centrifugation at 2500 × g for 10 minutes. Discard the 
supernatant.  
2. Wash the cells once by resuspending the cell pellet in wash buffer (e.g., PBS). Pellet cells by 
centrifugation at 2500 × g for 10 minutes.  
3. Add 300µl M-PER Reagent to the cell pellet. Pipette the mixture up and down to resuspend 
pellet.  
4. Shake mixture gently for 10 minutes. Remove cell debris by centrifugation at ~14,000 × g for 
15 minutes.  















DNEasy® Blood and Tissue Kit (QIAGEN) Citation [201]  
1. Cultured cells: Centrifuge the appropriate number of cells (maximum 5 x 106) for 
5 min at 300 x g. Resuspend the pellet in 200 μl PBS. Add 20 μl proteinase K. 
Continue with step 2. 
When using a frozen cell pellet, allow cells to thaw before adding PBS until the pellet can be 
dislodged by gently flicking the tube.  Ensure that an appropriate number of cells is used in the 
procedure. Add 4 μl RNase A (100 mg/ml), mix by vortexing, and incubate for 2 min at room 
temperature before continuing with step 2. 
2. Add 200 μl Buffer AL (without added ethanol). Mix thoroughly by vortexing, and incubate at 
56°C for 10 min.  It is essential that the sample and Buffer AL are mixed immediately and 
thoroughly by vortexing or pipetting to yield a homogeneous solution. 
3. Add 200 μl ethanol (96–100%) to the sample, and mix thoroughly by vortexing.  It is 
important that the sample and the ethanol are mixed thoroughly to yield a homogeneous solution. 
4. Pipet the mixture from step 3 into the DNeasy Mini spin column placed in a 2 ml collection 
tube (provided). Centrifuge at 6000 x g (8000 rpm) for 1 min. Discard flow-through and 
collection tube. 
5. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided), add 500 μl 
Buffer AW1, and centrifuge for 1 min at 6000 x g (8000 rpm). Discard flow-through and 
collection tube. 
6. Place the DNeasy Mini spin column in a new 2 ml collection tube (provided), add 500 μl 
Buffer AW2, and centrifuge for 3 min at 20,000 x g (14,000 rpm) to dry the DNeasy membrane. 
Discard flow-through and collection tube. It is important to dry the membrane of the DNeasy 
Mini spin column, since residual ethanol may interfere with subsequent reactions. This 
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centrifugation step ensures that no residual ethanol will be carried over during the following 
elution.  Following the centrifugation step, remove the DNeasy Mini spin column carefully so 
that the column does not come into contact with the flow-through, since this will result in 
carryover of ethanol. If carryover of ethanol occurs, empty the collection tube, then reuse it in 
another centrifugation for 1 min at 20,000 x g (14,000 rpm). 
7. Place the DNeasy Mini spin column in a clean 1.5 ml or 2 ml microcentrifuge tube (not 
provided), and pipet 200 μl Buffer AE directly onto the DNeasy membrane. Incubate at room 
temperature for 1 min, and then centrifuge for 1 min at 6000 x g (8000 rpm) to elute. Elution 
with 100 μl (instead of 200 μl) increases the final DNA concentration in the eluate, but also 
















RNEasy® Plus Micro Kit (QIAGEN) Citation [202]  
1. Cell samples were thawed and centrifuged at 300 x g for 5 minutes.  Supernatant was aspirated 
off and discarded.  
2. Cells disrupted cells by adding Buffer RLT Plus. 
For pelleted cells, loosen the cell pellet thoroughly by flicking the tube. Add 350 μl Buffer RLT 
Plus. Vortex or pipet to mix, and proceed to step 3. 
3. Homogenized the lysate by vortexing  
4. Lysate was transferred to a gDNA Eliminator spin column placed in a 2 ml collection tube 
(supplied). Centrifuge for 30 s at ≥8000 x g (≥10,000 rpm). Discarded the column, and saved the 
flow through. 
5. Added 350 μl of 70% ethanol to the flow-through from step 4, and mixed well by pipetting. 
Do not centrifuge. Proceed immediately to step 6. 
6. Transferred the sample, including any precipitate that may have formed, to an RNeasy 
MinElute spin column placed in a 2 ml collection tube (supplied). Closed the lid gently, and 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm). Discard the flow-through.* 
Reuse the collection tube in step 7. 
7. Added 700 μl Buffer RW1 to the RNeasy MinElute spin column. Closed the lid gently, and 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard the 
flow-through.* 
Reuse the collection tube in step 8. 
Note: After centrifugation, carefully remove the RNeasy MinElute spin column from the 
collection tube so that the column does not contact the flow-through. Be sure to empty the 
collection tube completely. 
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8. Added 500 μl Buffer RPE to the RNeasy MinElute spin column. Closed the lid gently, and 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard the 
flow-through. 
Reuse the collection tube in step 9. 
9. Added 500 μl of 80% ethanol to the RNeasy MinElute spin column. Closed the lid gently, and 
centrifuged for 2 min at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard 
the collection tube with the flow-through. 
Prepare the 80% ethanol with ethanol (96–100%) and the RNase-free water supplied with the kit. 
10. Placed the RNeasy MinElute spin column in a new 2 ml collection tube (supplied). Open the 
lid of the spin column, and centrifuge at full speed for 5 min. Discarded the collection tube with 
the flow-through. 
11. Placed the RNeasy MinElute spin column in a new 1.5 ml collection tube (supplied). Add 14 
μl RNase-free water directly to the center of the spin column membrane. Closed the lid gently, 













OneStep RT-PCR (QIAGEN) Citation [203] 
1. Thaw template RNA, primer solutions, dNTP Mix, 5x QIAGEN OneStep RT-PCR Buffer, and 
RNase-free water, and place them on ice. 
2. Prepare a master mix according to the table below. 
  Volume 
RNase free water 39 µl 
5x QIAGEN OneStep RT-PCR Buffer 10 µl 
dNTP Mix  2 µl 
F Primer  3 µl 
R Primer 3 µl 
QIAGEN OneStep RT-PCR Enzyme 
Mix 2 µl 
Template RNA 1 µl 
Total 50 µl 
 
3. Mix the master mix thoroughly, and dispense appropriate volumes into PCR tubes. Mix 
gently, for example, by pipetting the master mix up and down a few times. 
4. Add template RNA (≤ 2 μg/reaction) to the individual PCR tubes. 
5. Program the thermal cycler according to the program outlined in the table below. 
Reverse 
Transcription 30 minutes 50°C 
Initial PCR 
activation 15 minutes 95°C 
3 Step cycling     
Denaturation 30-60 seconds 94°C 
Annealing 30-60 seconds 50-68°C 
Extension 1 minute 72°C 
Number of cycles 25-40 cycles   
Final extension 10 minutes 72°C 
 
6. Start the RT-PCR program while PCR tubes are still on ice. Wait until the thermal cycler has 





PILOT STUDY USING BRUCELLA ABORTUS STRAIN 19 AS A MODEL FOR 
VIRULENT CHALLENGE IN GOATS 
 
Brucella is a genus of Gram negative, facultative intracellular pathogens named for their 
natural hosts with B. melitensis for goats and B. abortus for cattle [1, 5].  Infected cattle abort 
during the last trimester of pregnancy and secrete Brucella in milk [2, 68].  Human exposure 
occurs through unpasteurized milk, blood, lymph or tissues from infected animals and may result 
in undulant fever, arthritis, endocarditis, and spondylitis [2-4, 6, 11].  Globally, there are 
approximately 500,000 cases of human brucellosis reported each year and high economic 
burdens due to animal brucellosis in developing countries [12, 13].  In the United States, there 
are limited means of controlling brucellosis in wildlife reservoirs which are capable of spreading 
infection to domestic livestock [17, 204].   
Vaccination has proven to be effective in controlling brucellosis; however, further 
research is necessary to develop an ‘ideal’ vaccine [11, 14, 15, 69, 70].  While the mouse is the 
standard animal model for brucellosis vaccine development, results are not always applicable to 
the target species, such as cattle [17].  The caprine model has the advantage of using both a 
ruminant and natural host for Brucella spp. [68].  Goats infected with B. abortus develop similar 
clinical signs and serological response as cattle [205].  Goats are also less costly to maintain and 
have shorter gestation lengths than large ruminants [68].  Vaccine development is further 
complicated because the challenge strain B. abortus 2308 is a select agent, which is subject to 
strict regulations [206].  A possible solution to this obstacle is using Brucella spp. that are 
exempt from these regulations as the challenge, such as Strain 19 [207].  
The first widely used vaccine against bovine brucellosis in the U.S. was the live-
attenuated B. abortus Strain 19, which provides protection for the entire productive life span of 
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the animal [14, 69].  In domestic cattle, vaccination with Strain 19 combined with test and 
slaughter policies has been effective in controlling brucellosis in several countries [208, 209].  
While less protective, it can be used in wildlife control plans, as well [210-213].  Despite these 
benefits, Strain 19 has many negative qualities.  Vaccination with Strain 19 interferes with 
serological tests, which led to it being replaced by Strain RB51 in the United States [69, 73].   
Strain 19 also maintains a low level of virulence, may cause abortion in pregnant cattle, 
and remains pathogenic to humans [69].  Vaccination with Strain 19 is also known to cause 
orchitis and can be isolated from testicles of bulls [214, 215].  Though it is rare, some cattle 
remain chronically infected and excrete Strain 19 in milk [69, 209, 216].  The rate of chronic 
infection and abortion is higher in bison, which limits its use in wildlife control plans [212].   
It is known that goats abort and bacteria can be isolated from milk and fetal tissues when 
vaccinated with B. melitensis Rev. 1, another live-attenuated strain, during late pregnancy [217-
220].  Furthermore, abortion rate and shedding increases in a dose dependent manner with higher 
doses of Rev. 1 [219].  Due to its residual virulence and ability to infect ruminants other than 
cattle, we hypothesize that a sufficient dose of Strain 19 may mimic virulent challenge in both 
non-pregnant and pregnant goats.  
MATERIALS AND METHODS  
STRAIN 19 AND BACTERIAL CULTURE 
 Brucella abortus Strain 19 was obtained from laboratory stocks originally from the 
USDA and kept at -80°C.  Bacteria were grown on Schaedler agar (Remel, San Diego, CA) with 
Brucella Selective Supplement (Oxoid Inc, Nepean, ON) and 5% Horse serum (Sigma Life 
Science, St. Louis, MO) and incubated at 37°C with 5% CO2 and humidity.  Inoculation doses of 
Strain 19 were grown on the plates then collected by washing with PBS and pipetting off the 
liquid into vials.  The vials were confirmed to contain 1X1011 colony forming units (CFU)/ml by 
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serial dilution.  Vials were snap frozen and stored at -80°C until time of infection.  Before 
infection, vials were thawed and diluted in PBS to the appropriate concentrations and CFU/ml 
confirmed by serial dilutions.   
GOATS 
 All goats were bled, Card tested, and dewormed prior to infection.  For the transient 
colonization study, eight breeding age female Boer goats were housed at the Agriculture Center 
Isolation Facility (ACIF, Baton Rouge, LA) and acclimated for two weeks before infection.  
Goats were infected with either 1X109 or 1X1010 CFU by placing 50 µl inoculum in each 
conjunctival sac.  At two and four weeks post infection, two goats from each group were 
sacrificed by captive bolt and exsanguination.  Blood, parotid lymph node, prescapular lymph 
node, internal iliac lymph node, supramammary lymph node, liver, and spleen samples were 
taken at the time of sacrifice.  Tissue samples were stored at -20°C until testing. 
 All goats were bled, Card tested and dewormed prior to infection and exposure to bucks.  
Does were exposed to two bucks for 60 days.  Pregnancy status and gestation length were 
confirmed by ultrasound.  Thirteen pregnant does were housed at ACIF and acclimated for two 
weeks prior to infection at approximately 100 days gestation.  The treatment groups (4 goats 
each) were infected with either 1X109 or 1X1010 CFU via 50 µl inoculum in each conjunctival 
sac (CJ).  The positive control group (5 goats) was infected with 1X107 CFU via intravenous 
(IV) injection.  Goats were monitored twice a day, and parturition status was recorded as live or 
dead.  Kids were euthanized by CO2 asphyxiation and exsanguination immediately after 
parturition.  Fetal lung, spleen and abomasal fluid samples were collected and stored at -20°C 
until testing.  Milk samples were taken 2-4 weeks post-parturition and stored at -20°C until 
testing.  Maternal blood samples were taken at 2-4 weeks and 4-6 weeks post parturition. 
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SERA, MILK AND TISSUE SAMPLES 
   Blood samples were allowed to clot at room temperature then centrifuged at 3400g, and 
sera was pipetted off and stored at -20°C until testing.  Card tests were performed on sera 
samples to determine serological status.  Lymph node, spleen and liver samples were thawed; 
and ground with a Bullet Blender 50 (Next Advance, Averill Park, NY); and 100 µl aliquots 
were plated.  Aliquots of abomasal fluid and milk were plated (100 µl).  Fetal lung samples were 
tested for bacteria by blotting.  Briefly, lung samples were dipped in 70% ethanol then blotted 
dry on sterile gauze.  Lung tissue was cut with sterile scissors and the exposed tissue pressed 
against the Schaedler agar.  Final CFU/ml and CFU/gram of tissue were determined after three 
weeks of incubation.   
BRUCELLA IDENTIFICATION 
 Suspected B. abortus Strain 19 colonies were confirmed by Gram stain, colony 
morphology, oxidase, catalase, urease, H2S and TSI biochemical tests.   
STATISTICS 





 All goats were Card negative pre-infection.  Post-infection, one goat challenged with 
1X109 CFU was Card negative while all others tested positive (Table 3).  At 14 days post 
infection, Strain 19 was isolated from all lymph node, spleen, and liver samples of the 1X1010 
group, while the 1X109 group only displayed bacteria in the parotid lymph node (Table 1 and 
Table 2).  At 28 days post infection, one goat in the 1X109 group was colonized in all tissue 
samples taken, while the other goat in the group only had Strain 19 recovered from the parotid 
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lymph node.  In the 1X1010 group, the prescapular lymph node, supramammary lymph node, and 
spleen were colonized in only one goat (Table 2). 
 
1X109 Par   PS  SM II  Spl LV 
14 days 250 (2.40) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
14 days  121.28 (2.08) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
28 days 287.88 (2.46)  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
28 days 7320.2 (3.86) 225.42 (2.35) 95.32 (1.98) 109.2 (2.04) 108.69 (2.04) 28.27 (1.45) 
 
Table 1. 
CFU/g (Log/g of tissue) of B. abortus Strain 19 recovered from tissue of goats infected with 
1X109 at 14 and 28 days postinfection. Parotid lymph node (Par), Prescapular lymph node (PS), 
supramammary lymph node (SM), internal iliac lymph node (II), spleen (Spl), and liver (LV) 
samples. 
 
1X1010 Par  PS SM II  Spl LV 
14 days  9223.3 (3.96) 84.82 (1.93) 143.94 (2.16) 120.25 (2.08) 8520.18 (3.93) 0 (0) 
14 days  2900.76 (3.46) 201.7 (2.3) 246.75 (2.39) 226.19 (2.35) 1187.5 (3.07) 23.17 (1.36) 
28 days 604.05 (2.78) 0 (0) 0 (0) 0 (0) 27.14 (1.43) 0 (0) 
28 days 7587.86 (3.88) 791.67 (2.90) 284.43 (2.45) 0 (0) 0 (0) 0 (0) 
 
Table 2.  
CFU/g (Log/g of tissue) of B. abortus Strain 19 recovered from tissue goats infected with 1X1010 
at 14 and 28 days postinfection.  Parotid lymph node (Par), Prescapular lymph node (PS), 
supramammary lymph node (SM), internal iliac lymph node (II), spleen (Spl), and liver (LV) 
samples. 
 
  14 days 28 days 
1X109 50% 100% 
1X1010 100% 100% 
 
Table 3. 
Percent of Card positive nonpregnant goats at 14 and 28 days postinfection with 1X109 or 
1X1010 CFU of B. abortus Strain 19. 
 
PREGNANT CHALLENGE 
 All does were Rose Bengal card test negative prior to infection.  Table 4 shows the 
serological status of the does at 2-4 and 4-6 weeks post parturition.  Sonograms were used to 
estimate gestation length within 21 days.  Average gestation lengths (Table 5) are within 21 days 
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of the average 150 days of normal caprine gestation.  All kids were born alive; and no Strain 19 
was recovered from any of the milk, fetal lung, fetal spleen, or abomasal fluid samples (data not 
shown).  
  CJ 10
9 CJ 1010 IV 107 
2-4 weeks 50% 75% 50% 
4-6 weeks 50% 66% 50% 
 
Table 4. 
Percent Card positive at 2-4 and 4-6 weeks post parturition.  Goats were infected at 
approximately 100 days gestation with B. abortus Strain 19 either conjunctively (CJ) or 






1X109 CJ 129.25 
1X1010 CJ 133.25 
1X107 IV 129.25 
 
Table 5. 
Estimated gestation length based on sonograms. All groups are within the normal gestation 
length of 150 days for caprine pregnancy. 
 
DISCUSSION 
The transient colonization study performed suggests that Strain 19 colonization is 
consistent with the profile of an attenuated mutant in the caprine model [68].  The liver, spleen, 
and all lymph nodes were colonized by 14 days post infection in the 1X1010 CFU group (Table 
2).  In contrast to virulent Brucella strains [68], Strain 19 was clearing from the animal by 28 
days post-infection (Table 2).  The lower dose, 1X109 CFU, disseminated slowly and was only 
detectable beyond the parotid lymph node in one goat sacrificed at 28 days post infection (Table 
1).  All animals except one were Card positive at time of sacrifice (Table 3).  The Card negative 
animal was from the 1X109 CFU group sacrificed at 14 days post inoculation, and Strain 19 had 
not disseminated to tissues beyond the parotid lymph node.   
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The virulent challenge B. abortus caprine model produces consistent results in pregnant 
goats; 30-50% abort and 50-70% dam kid pair colonization [68].  Further, goats infected with B. 
abortus 2308 during the third trimester of pregnancy shed bacteria in milk [221].  The Card test 
indicates that 50-75% of the pregnant goats were transiently colonized by Strain 19 (Table 4).  
However, the conjunctival and intravenous challenge with attenuated Strain 19 resulted in no 
abortions; and bacteria was not recovered from milk, fetal tissue, or abomasal fluid samples 
(Table 4 and Table 5).   
The inability of B. abortus Strain 19 to induce abortion might be due to infection 
occurring in a non-native host.  It has been shown that B. abortus induces less lesions in pregnant 
goats than pregnant cows [222].  Furthermore, virulent B. melitensis challenge results in both 
higher abortion (70-100%) and dam kid pair colonization (90-100%) rates than B. abortus in the 
caprine model [68].  Based on previous research, the live-attenuated vaccine B. melitensis Rev. 1 
persists in goats longer than B. abortus Strain 19 [223].  Three weeks after vaccination, Rev. 1 
can be isolated be the spleen, liver and systemic lymph nodes and begins to clear between weeks 
three and five.  The bacteria persist only in the prefemoral and prescapular lymph nodes after 
eight weeks [223].  Despite not being directly comparable, our data suggests that B. abortus 
Strain 19 and B. melitensis Rev. 1 are in a similar stage of clearance from the goat at four and 
eight weeks post infection, respectively [223] (Table 4 and Table 5). 
The intravenous inoculation route immediately induces bacteremia in the animal, 
suggesting that Strain 19 was not able to cross the caprine placenta or crossed the placenta but 
failed to colonize the fetus.  Studies indicate that complications due to Strain 19 vaccination in 
cows are rare.  The vaccine strain induces abortion and is shed in the milk of only 1-5% and 
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1.9% of vaccinated cows, respectively [224-227].  Our results suggest that Strain 19 is similarly 
attenuated in the caprine model.   
CONCLUSION 
 Animal brucellosis causes high economic burdens and infects over half a million people a 
year worldwide [12, 13].  Development of improved vaccines is limited by regulations on the 
virulent strains of Brucella spp [206].  The purpose of this study was to determine if the live-
attenuated vaccine Strain 19 could mimic a virulent B. abortus challenge in the caprine model.  
Transient colonization was established in non-pregnant goats, with the higher inoculation dose 
disseminating more rapidly and bacteria clearing from the animals by 28 days post challenge 
(Table 1 and 2).  Pregnant goats challenged with Strain 19 did not abort; and no bacteria were 
recovered from milk, fetal lung, spleen, or abomasal fluid.  This suggests that B. abortus Strain 
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